СОВРЕМЕННЫЕ ПОДХОДЫ К ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ГРАНУЛЕЗОКЛЕТОЧНЫХ ОПУХОЛЕЙ ЯИЧНИКОВ

Subject Terms: гранулезоклеточная опухоль, рак яичников, иммуногистохимия, молекулярно-генетический анализ, онкомаркеры, FOXL2, хирургическое лечение, химиотерапия, гормональная терапия, таргетная терапия, NCCN, RUSSCO, персонализированная медицина, жидкостная биопсия, иммунотерапия

СОВРЕМЕННЫЕ ПОДХОДЫ К ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ГРАНУЛЕЗОКЛЕТОЧНЫХ ОПУХОЛЕЙ ЯИЧНИКОВ

Subject Terms: гранулезоклеточная опухоль, рак яичников, иммуногистохимия, молекулярно-генетический анализ, онкомаркеры, FOXL2, хирургическое лечение, химиотерапия, гормональная терапия, таргетная терапия, NCCN, RUSSCO, персонализированная медицина, жидкостная биопсия, иммунотерапия

The role of local estriol therapy in comprehensive management of women with genitourinary menopausal syndrome: clinical observation series ; Роль локальной гормональной терапии эстриолом в комплексном ведении женщин с генитоуринарным менопаузальным синдромом: серия клинических наблюдений

Authors: I. A. Apolikhina, E. A. Gorbunova, A. S. Saidova, L. A. Tarnaeva, И. А. Аполихина, Е. А. Горбунова, А. С. Саидова, Л. А. Тарнаева

Contributors: The authors declare no funding, Авторы заявляют об отсутствии финансирования

Source: Obstetrics, Gynecology and Reproduction; Vol 19, No 5 (2025); 788-799 ; Акушерство, Гинекология и Репродукция; Vol 19, No 5 (2025); 788-799 ; 2500-3194 ; 2313-7347

Subject Terms: прилокаин, GUMS, postmenopause, estriol, pelvic organ prolapse, stress incontinence, hyperactive bladder, sling urethropexy, local hormone therapy, decubital ulcer, dyspareunia, vaginal dryness, laser rejuvenation, fractional photothermolysis, aesthetic gynecology, EMLA, lidocaine, prilocaine, ГУМС, постменопауза, эстриол, пролапс тазовых органов, стрессовое недержание мочи, гиперактивный мочевой пузырь, слинговая уретропексия, локальная гормональная терапия, декубитальная язва, диспареуния, вагинальная сухость, лазерное омоложение

File Description: application/pdf

Relation: https://www.gynecology.su/jour/article/view/2599/1400; Клинические рекомендации. Менопауза и климактерическое состояние у женщины. М.: Министерство здравоохранения Российской Федерации, 2024. 93 с. Режим доступа: https://drive.google.com/file/d/1S8V8Tg-SXj3Nms4uZvkau47LRHzuVhXn/view. [Дата обращения: 15.06.2025].; Vodegel E.V., Kastelein A.W., Jansen C.H.J.R. et al. The effects of oestrogen on vaginal wound healing: A systematic review and meta-analysis. Neurourol Urodyn. 2022;41(1):115–26. https://doi.org/10.1002/NAU.24819.; Abrams P., Cardozo L., Fall M. et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. https://doi.org/10.1016/S0090-4295(02)02243-4.; ICS Standards 2022. Режим доступа: https://www.ics.org/members/shop/icsstandards2022. [Дата обращения: 15.06.2025].; Rossouw J.E., Anderson G.L., Prentice R.L. et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. J Am Med Assoc. 2002;288(3):321–33. https://doi.org/10.1001/JAMA.288.3.321.; Sturdee D.W., Panay N.; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509–22. https://doi.org/10.3109/13697137.2010.522875.; Chapple C.R., Siddiqui E. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia. Expert Rev Clin Pharmacol. 2017;10(2):131–51. https://doi.org/10.1080/17512433.2017.1275570.; Nager C.W. Brubaker L., Litman H.J. et al.; Urinary Incontinence Treatment Network. A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med. 2012;366(21):1987–97. https://doi.org/10.1056/NEJMOA1113595.; Weber M.A., Kleijn M.H., Langendam M. et al. Local oestrogen for pelvic floor disorders: a systematic review. PLoS One. 2015;10(9):e0136265. https://doi.org/10.1371/JOURNAL.PONE.0136265.; Rahn D.D., Carberry C., Sanses T.V. et al.; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause. Obstet Gynecol. 2014;124(6):1147–56. https://doi.org/10.1097/AOG.0000000000000526.; Castelo-Branco C., Cancelo M.J., Villero J. et al. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. 2005;52 Suppl 1:S46–52. https://doi.org/10.1016/j.maturitas.2005.06.014.; Клинические рекомендации – Недержание мочи – 2024-2025-2026 (07.08.2024). М.: Министерство здравоохранения Российской Федерации, 2024. 40 с. Режим доступа: http://disuria.ru/_ld/14/1449_kr24N39R32MZ.pdf. [Дата обращения: 15.06.2025].; Marschalek M.L., Bodner K., Kimberger O. et al. Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study. BJOG. 2021;128(13):2200–08. https://doi.org/10.1111/1471-0528.16894.; Chen Y.Y., Su T.H., Lau H.H. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J. 2021;32(1):17–25. https://doi.org/10.1007/S00192-020-04397-Z.; Su I.H., Chen Y-C., Hwang W.-T. et al. Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women. Menopause. 2012;19(8):931–41. https://doi.org/10.1097/GME.0B013E31824362FF.; Kingsberg S.A., Wysocki S., Magnus L., Krychman M.L. Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE (REal women’s VIews of treatment options for menopausal vaginal changEs) survey. J Sex Med. 2013;10(7):1790–9. https://doi.org/10.1111/JSM.12190.; Coyne K.S., Sexton C.C., Irwin D.E. et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–95. https://doi.org/10.1111/J.1464-410X.2008.07601.X.; Koirala R., Gargari G., Arioli S. et al. Effect of oral consumption of capsules containing Lactobacillus paracasei LPC-S01 on the vaginal microbiota of healthy adult women: a randomized, placebo-controlled, double-blind crossover study. FEMS Microbiol Ecol. 2020;96(6):fiaa084. https://doi.org/10.1093/FEMSEC/FIAA084.; Athanasiou S., Pitsouni E., Grigoriadis T. et al. Mirabegron in female patients with overactive bladder syndrome: What’s new? A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020;251:73–82. https://doi.org/10.1016/j.ejogrb.2020.05.018.; Mension E., Alonso I., Tortajada M. et al. Vaginal laser therapy for genitourinary syndrome of menopause – systematic review. Maturitas. 2022;156:37–59. https://doi.org/10.1016/j.maturitas.; https://www.gynecology.su/jour/article/view/2599

Availability: https://www.gynecology.su/jour/article/view/2599
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2025.668

Menopause, postmenopausal osteoporosis, and dental implantation: the role of menopausal hormone therapy ; Менопауза, постменопаузальный остеопороз и дентальная имплантация: роль менопаузальной гормональной терапии

Authors: E. V. Medvedeva, N. V. Ivanov, A. F. Vesnina, E. A. Khromova, Sh. K. Yusupova, Е. В. Медведева, Н. В. Иванов, А. Ф. Веснина, Е. А. Хромова, Ш. К. Юсупова

Source: Obstetrics, Gynecology and Reproduction; Online First ; Акушерство, Гинекология и Репродукция; Online First ; 2500-3194 ; 2313-7347

Subject Terms: альвеолярная кость, dental implantation, menopausal hormone therapy, bioidentical sex hormones, antiresorptive therapy, osteoanabolic therapy, alveolar bone, дентальная имплантация, менопаузальная гормональная терапия, биоидентичные половые гормоны, антирезорбтивная терапия, остеоанаболическая терапия

File Description: application/pdf

Relation: https://www.gynecology.su/jour/article/view/2578/1387; Baber R., Panay N., Fenton A. IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50. https://doi.org/10.3109/13697137.2015.1129166.; Симонова Г.И., Лила А.М., Торопцова Н.В., Беневоленская Л.И. Остеопороз: современное состояние проблемы. Научно-практическая ревматология. 2019;57(6):653–60. https://doi.org/10.17116/terarkh201789590-97.; Eastell R., Rosen C.J., Black D.M. et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2019;104(5):1595–622. https://doi.org/10.1210/jc.2019-00221.; Reginster J.-Y., Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(2):4–9. https://doi.org/10.1016/j.bone.2005.11.024.; Lane N.E. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2 Suppl):S3–11. https://doi.org/10.1016/j.ajog.2005.08.047.; Temmerman A., Rasmusson L., Kubler A., Thor A. A prospective, randomized, controlled clinical trial on the long-term effect of osteoporosis on implant treatment. Clin Oral Implants Res. 2017;28(2):171–80. https://doi.org/10.1177/0022034518798804.; Alsaadi G., Quirynen M., Komarek A., van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. J Clin Periodontol. 2007;34(7):610–7. https://doi.org/10.1111/j.1600-051x.2007.01077.x.; Hernlund E., Svedbom A., Ivergard M. et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos. 2013;8:136. https://doi.org/10.1007/s11657-013-0136-1.; International Osteoporosis Foundation. Facts and statistics. Режим доступа: https://www.osteoporosis.foundation/facts-statistics. [Дата обращения: 28.08.2025].; Торопцова Н.В., Беневоленская Л.И., Лила А.М. Распространенность остеопороза и переломов в Российской Федерации: данные многоцентрового эпидемиологического исследования. Научно-практическая ревматология. 2018;56(1):15–23.; Dervis E. Oral implications of osteoporosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(3):349–56. https://doi.org/10.1016/j.tripleo.2005.04.010.; Zhu L., Zhou C., Chen S. et al. Osteoporosis and alveolar bone health in periodontitis niche: a predisposing factors-centered review. Cells. 2022;11(21):3380. https://doi.org/10.3390/cells11213380.; Khosla S., Oursler M.J., Monroe D.G. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576–81. https://doi.org/10.1016/j.tem.2012.03.008.; Prior J.C., Seifert-Klauss V.R., Giustini D. et al. Estrogen-progestin therapy causes a greater increase in spinal bone mineral density than estrogen therapy – a systematic review and meta-analysis of controlled trials with direct randomization. J Musculoskelet Neuronal Interact. 20171;17(3):146–54.; Prior J.C. Progesterone for the prevention and treatment of osteoporosis in women. Climacteric. 2018;21(4):366–74. https://doi.org/10.1080/13697137.2018.1467400.; Mills E.G., Yang L., Nielsen M.F. et al. The relationship between bone and reproductive hormones beyond estrogens and androgens. Endocr Rev. 2021;42(6):691–719. https://doi.org/10.1210/endrev/bnab015.; Sun L., Peng Y., Sharrow A.C. et al. FSH directly regulates bone mass. Cell. 2006;125(2):247–60. https://doi.org/10.1016/j.cell.2006.01.051.; Grey A.B. The skeletal effects of primary hyperparathyroidism. Baillieres Clin Endocrinol Metab. 1997;11(1):101–16. https://doi.org/10.1016/s0950-351x(97)80537-x.; Zaidi M., Moonga B.S., Huang C.L. Calcitonin and bone formation: a knockout full of surprises. J Clin Invest. 2002;110(12):1769–71. https://doi.org/10.1172/jci17425.; Giustina A., Mazziotti G., Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535–59. https://doi.org/10.1210/er.2007-0036.; Rosen C.J. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med. 1999;222(2):103–11. https://doi.org/10.3181/00379727-206-43726.; Zaidi M., Davies T.F., Zallone A. et al. Thyroid-stimulating hormone, thyroid hormones, and bone loss. Curr Osteoporos Rep. 2009;7(2):47–52. https://doi.org/10.1007/s11914-009-0009-0.; Arpaci D., Saglam F., Cuhaci F.N. et al. Serum testosterone does not affect bone mineral density in postmenopausal women. Arch Endocrinol Metab. 2015;59(4):292–6. https://doi.org/10.1590/2359-3997000000085.; Tao M.F., Sun D.M., Shao H.F. Low serum testosterone is associated with osteoporosis in postmenopausal women. Gynecol Endocrinol. 2022;38(5):409–13. https://doi.org/10.1080/09513590.2021.1930977.; Zhang H., Ma K., Li R.M. et al. Association between testosterone levels and bone mineral density in females aged 40-60 years from NHANES 2011-2016. Sci Rep. 202230;12(1):16426. https://doi.org/10.1038/s41598-022-21008-7.; Weinstein R.S. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41(3):595–611. https://doi.org/10.1016/j.ecl.2012.04.004.; Takeda S., Elefteriou F., Levasseur R. et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111(3):305–17. https://doi.org/10.1016/s0092-8674(02)01049-8.; Holick M.F. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81. https://doi.org/10.1056/NEJMra070553.; Hoppé E., Bouvard B., Royer M. et al. Sex hormone-binding globulin in osteoporosis. Joint Bone Spine. 2010;77(4):306–12. https://doi.org/10.1016/j.jbspin.2010.03.011.; Weitzmann M.N. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo). 2013;2013:125705. https://doi.org/10.1155/2013/125705.; Jeffcoat M.K. Osteoporosis: a possible modifying factor in oral bone loss. Ann Periodontol. 1998;3(1):312–21. https://doi.org/10.1902/annals.1998.3.1.312.; Dvorak G., Arnhart C., Heuberer S. et al. Peri-implantitis and late implant failures in postmenopausal women: a cross-sectional study. J Clin Periodontol. 2011;38(10):950–5. https://doi.org/10.1111/j.1600-051X.2011.01772.x.; Karoussis I.K., Müller S., Salvi G.E. et al. Association between periodontal and peri-implant conditions: a 10-year prospective study. Clin Oral Implants Res. 2004;15(1):1–7. https://doi.org/10.1111/j.1600-0501.2004.00982.x.; Black D.M., Rosen C.J. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–62. https://doi.org/10.1056/nejmc1602599.; Ruggiero S.L., Dodson T.B., Fantasia J. et al. Medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–56. https://doi.org/10.1016/j.joms.2014.04.031.; Khan A.A., Morrison A., Hanley D.A. et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23. https://doi.org/10.1002/jbmr.2405.; Kuchler U., Luvizuto E.R., Tangl S. et al. Short-term teriparatide delivery and osseointegration: a clinical feasibility study. J Dent Res. 2011;90(8):1001–6. https://doi.org/10.1177/0022034511407920.; Bashutski J.D., Eber R.M., Kinney J.S. et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med. 2010;363(25):2396–405. https://doi.org/10.1056/NEJMoa1005361.; Miller P.D., Hattersley G., Riis B.J. et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: the ACTIVE randomized clinical trial. JAMA. 2016;316(7):722–33. https://doi.org/10.1001/jama.2016.11136.; Tabatabai L., Cosman F., Curtis J.R. et al. Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective. Analysis. Endocr Pract. 2025;31(2):159–68. https://doi.org/10.1016/j.eprac.2024.10.017.; Cosman F., Crittenden D.B., Adachi J.D. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43. https://doi.org/10.1056/NEJMoa1607948.; McClung M.R., Grauer A., Boonen S. et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20. https://doi.org/10.1056/NEJMoa1305224.; Giro G., Chambrone L., Goldstein A. et al. Impact of menopause hormone therapy on dental implant outcomes: a 5-year prospective study. Clin Implant Dent Relat Res. 2019;21(5):936–44. https://doi.org/10.1111/cid.12779.; Stanczyk F.Z., Archer D.F., Bhavnani B.R. Ethinyl estradiol and 17β-estradiol in contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87(6):706–27. https://doi.org/10.1016/j.contraception.2012.12.011.; https://www.gynecology.su/jour/article/view/2578

Availability: https://www.gynecology.su/jour/article/view/2578
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2025.678

НАРУШЕНИЯ СНА ПОСЛЕ КЛИМАКСА У ЖЕНЩИН

Authors: Азимджонова, Ш. Х., Абдуллаева, М. А.

Source: JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH; Vol. 4 No. 10 (2025): Journal of Healthcare and Life-Science Research; 81-84

Subject Terms: климакс, менопауза, нарушения сна, бессонница, вазомоторные симптомы, KNDy, fezolinetant, менопаузальная гормональная терапия

File Description: application/pdf

Relation: https://jhlsr.innovascience.uz/index.php/jhlsr/article/view/1604/1414; https://jhlsr.innovascience.uz/index.php/jhlsr/article/view/1604

Availability: https://jhlsr.innovascience.uz/index.php/jhlsr/article/view/1604

Premature Ovarian Insufficiency in Patients with Autoimmune Diseases ; Преждевременная недостаточность яичников у пациенток с аутоиммунными заболеваниями

Authors: Irina V. Karachentsova, Elena V. Sibirskaya, Ulyana A. Krainova, Veronika D. Mospan, Mariia Yu. Chernysheva, И. В. Караченцова, Е. В. Сибирская, У. А. Крайнова, В. Д. Моспан, М. Ю. Чернышева

Contributors: Not specified, Отсутствует

Source: Pediatric pharmacology; Том 22, № 3 (2025); 333-340 ; Педиатрическая фармакология; Том 22, № 3 (2025); 333-340 ; 2500-3089 ; 1727-5776

Subject Terms: клеточная терапия, autoimmune diseases, amenorrhea, estrogen deficiency, premature menopause, Addison’s disease, hypothyroidism, hormone replacement therapy, cell therapy, аутоиммунные заболевания, аменорея, дефицит эстрогенов, преждевременная менопауза, болезнь Аддисона, гипотиреоз, заместительная гормональная терапия

File Description: application/pdf

Relation: https://www.pedpharma.ru/jour/article/view/2648/1715; Vogt EC, Real FG, Husebye ES, et al. Premature menopause and autoimmune primary ovarian insufficiency in two international multicenter cohorts. Endocr Connect. 2022;11(5):e220024. doi: https://doi.org/10.1530/EC-22-0024; Табеева Г.И., Шамилова Н.Н., Жахур Н.А. и др. Преждевременная недостаточность яичников — загадка XXI века // Акушерство и гинекология. — 2013. — № 12. — С. 16–21.; Караченцова И.В., Сибирская Е.В., Хайруллина А.А. Преждевременная недостаточность яичников у пациенток с галактоземией // Педиатрическая фармакология. — 2024. — Т. 21. — № 2. — С. 119–125. — doi: https://doi.org/10.15690/pf.v21i2.2721; Komorowska B. Autoimmune premature ovarian failure. Prz Menopauzalny. 2016;15(4):210–214. doi: https://doi.org/10.5114/pm.2016.65666; Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal.j Assist Reprod Genet. 2019;36(11):2207–2215. doi: https://doi.org/10.1007/s10815-019-01572-0.; Szeliga A, Calik-Ksepka A, Maciejewska-Jeske M, et al. Autoimmune Diseases in Patients with Premature Ovarian Insufficiency-Our Current State of Knowledge. Int J Mol Sci. 2021;22(5):2594. doi: https://doi.org/10.3390/ijms22052594; Collins G, Patel B, Thakore S, Liu J. Primary Ovarian Insufficiency: Current Concepts. South Med J. 2017;110(3):147–153. doi: https://doi.org/10.14423/SMJ.0000000000000611; Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937. doi: https://doi.org/10.1093/humrep/dew027; Nelson LM, Bakalov VK. Mechanisms of follicular dysfunction in 46,XX spontaneous premature ovarian failure. Endocrinol Metab Clin North Am. 2003;32(3):613–637. doi: https://doi.org/10.1016/s0889-8529(03)00043-4; Ebrahimi M, Akbari Asbagh F. The role of autoimmunity in premature ovarian failure. Iran J Reprod Med. 2015;13(8):461–472.; Bannatyne P, Russell P, Shearman RP. Autoimmune oophoritis: a clinicopathologic assessment of 12 cases. Int J Gynecol Pathol. 1990;9(3):191–207. doi: https://doi.org/10.1097/00004347-199007000-00001; Sedmak DD, Hart WR, Tubbs RR. Autoimmune oophoritis: a histopathologic study of involved ovaries with immunologic characterization of the mononuclear cell infiltrate. Int J Gynecol Pathol. 1987;6(1):73.; Kobayashi M, Nakashima A, Yoshino O, et al. Decreased effector regulatory T cells and increased activated CD4+ T cells in premature ovarian insufficiency. Am J Reprod Immunol. 2019;81(6):e13125. doi: https://doi.org/10.1111/aji.13125; Xiong J, Tan R, Wang W, et al. Evaluation of CD4+CD25+FOXP3+ regulatory T cells and FOXP3 mRNA in premature ovarian insufficiency. Climacteric. 2020;23(3):267–272. doi: https://doi.org/10.1080/13697137.2019.1703938; Dal Pra C, Chen S, Furmaniak J, et al. Autoantibodies to steroidogenic enzymes in patients with premature ovarian failure with and without Addison’s disease. Eur J Endocrinol. 2003;148(5):565–570. doi: https://doi.org/10.1530/eje.0.1480565; Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. Endocr Rev. 1997;18(1):107–134. doi: https://doi.org/10.1210/edrv.18.1.0291; Bakalov VK, Vanderhoof VH, Bondy CA, Nelson LM. Adrenal antibodies detect asymptomatic auto-immune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod. 2002;17(8):2096–2100. doi: https://doi.org/10.1093/humrep/17.8.2096; Novosad JA, Kalantaridou SN, Tong ZB, Nelson LM. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. BMC Womens Health. 2003;3(1):2. doi: https://doi.org/10.1186/1472-6874-3-2; Monteleone P, Parrini D, Faviana P, et al. Female infertility related to thyroid autoimmunity: the ovarian follicle hypothesis. Am J Reprod Immunol. 2011;66(2):108–114. doi: https://doi.org/10.1111/j.1600-0897.2010.00961.x; Dittrich R, Beckmann MW, Oppelt PG, et al. Thyroid hormone receptors and reproduction.j Reprod Immunol. 2011;90(1):58–66. doi: https://doi.org/10.1016/j.jri.2011.02.009; Medenica S, Garalejic E, Arsic B, et al. Follicular fluid thyroid autoantibodies, thyrotropin, free thyroxine levels and assisted reproductive technology outcome. PLoS One. 2018;13(10):e0206652. doi: https://doi.org/10.1371/journal.pone.0206652; Zhong YP, Ying Y, Wu HT, et al. Relationship between antithyroid antibody and pregnancy outcome following in vitro fertilization and embryo transfer. Int J Med Sci. 2012;9(2):121–125. doi: https://doi.org/10.7150/ijms.3467; Ahonen P, Miettinen A, Perheentupa J. Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure.j Clin Endocrinol Metab. 1987;64(3):494–500. doi: https://doi.org/10.1210/jcem-64-3-494; Reato G, Morlin L, Chen S, et al. Premature ovarian failure in patients with autoimmune Addison’s disease: clinical, genetic, and immunological evaluation.j Clin Endocrinol Metab. 2011;96(8):E1255–E1261. doi: https://doi.org/10.1210/jc.2011-0414; Meloni A, Willcox N, Meager A, et al. Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients.j Clin Endocrinol Metab. 2012;97(4):1114–1124. doi: https://doi.org/10.1210/jc.2011-2461; Michels AW, Gottlieb PA. Autoimmune polyglandular syndromes. Nat Rev Endocrinol. 2010;6(5):270–277. doi: https://doi.org/10.1038/nrendo.2010.40; Szlendak-Sauer K, Jakubik D, Kunicki M, et al. Autoimmune polyglandular syndrome type 3 (APS-3) among patients with premature ovarian insufficiency (POI). Eur J Obstet Gynecol Reprod Biol. 2016;203:61–65. doi: https://doi.org/10.1016/j.ejogrb.2016.05.023; Welt CK. Autoimmune oophoritis in the adolescent. Ann N Y Acad Sci. 2008;1135:118–122. doi: https://doi.org/10.1196/annals.1429.006; Podfigurna-Stopa A, Czyzyk A, Grymowicz M, et al. Premature ovarian insufficiency: the context of long-term effects.j Endocrinol Invest. 2016;39(9):983–990. doi: https://doi.org/10.1007/s40618-016-0467-z; Luisi S, Orlandini C, Regini C, et al. Premature ovarian insufficiency: from pathogenesis to clinical management.j Endocrinol Invest. 2015;38(6):597–603. doi: https://doi.org/10.1007/s40618-014-0231-1; Akawatcharangura P, Taechakraichana N, Osiri M. Prevalence of premature ovarian failure in systemic lupus erythematosus patients treated with immunosuppressive agents in Thailand. Lupus. 2016;25(4):436–444. doi: https://doi.org/10.1177/0961203315617539; Шабанова С.Ш., Ананьева Л.П., Алекберова З.С. Терапия циклофосфаном и овариальная недостаточность у больных системной красной волчанкой // Научно-практическая ревматология. — 2003. — Т. 41. — № 3. — С. 63–67. — doi: https://doi.org/10.14412/1995-4484-2003-1364; Mayorga J, Alpízar-Rodríguez D, Prieto-Padilla J, et al. Prevalence of premature ovarian failure in patients with systemic lupus erythematosus. Lupus. 2016;25(7):675–683. doi: https://doi.org/10.1177/0961203315622824; Юренева С.В., Аверкова В.Г. Вазомоторные симптомы в менопаузе: центральные триггеры, эффекторы и новые возможности патогенетической терапии // Российский вестник акушера-гинеколога. — 2018. — Т. 18. — № 5. — С. 43–48. — doi: https://doi.org/10.17116/rosakush20181805143; Макацария А.Д., Блинов Д.В., Бицадзе В.О., Хизроева Д.Х. Лечение эстриолом вульвовагинальной атрофии в постменопаузе: обновление научных данных 2014–2018 гг. // Акушерство, Гинекология и Репродукция. — 2019. — Т. 13. — № 3. — С. 227–238. — doi: https://doi.org/10.17749/2313-7347.2019.13.227-238; Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric. 2015;18(4):483–491. doi: https://doi.org/10.3109/13697137.2015.1020484; Kalantaridou SN, Calis KA, Vanderhoof VH, et al. Testosterone deficiency in young women with 46,XX spontaneous premature ovarian failure. Fertil Steril. 2006;86(5):1475–1482. doi: https://doi.org/10.1016/j.fertnstert.2006.04.028; Jiao X, Zhang H, Ke H, et al. Premature Ovarian Insufficiency: Phenotypic Characterization Within Different Etiologies.j Clin Endocrinol Metab. 2017;102(7):2281–2290. doi: https://doi.org/10.1210/jc.2016-3960; Кумыкова З.Х., Уварова Е.В., Батырова З.К. Современные подходы к оценке и сохранению овариального резерва у девочек-подростков с преждевременной недостаточностью яичников // Репродуктивное здоровье детей и подростков. — 2022. — Т. 18. — № 3. — С. 34–45. — doi: https://www.doi.org/10.33029/1816-2134-2022-18-3-34-45; Gleicher N, Kushnir VA, Barad DH. Prospectively assessing risk for premature ovarian senescence in young females: a new paradigm. Reprod Biol Endocrinol. 2015;13:34. doi: https://doi.org/10.1186/s12958-015-0026-z; La Marca A, Marzotti S, Brozzetti A, et al. Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles.j Clin Endocrinol Metab. 2009;94(10):3816–3823. doi: https://doi.org/10.1210/jc.2009-0817; Bidet M, Bachelot A, Bissauge E, et al. Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure.j Clin Endocrinol Metab. 2011;96(12):3864–3872. doi: https://doi.org/10.1210/jc.2011-1038; Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016;106(7):1588–1599. doi: https://doi.org/10.1016/j.fertnstert.2016.09.046; Langrish JP, Mills NL, Bath LE, et al. Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension. 2009;53(5):805–811. doi: https://doi.org/10.1161/HYPERTENSIONAHA.108.126516; Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489–3510. doi: https://doi.org/10.1210/jc.2014-2260; Elias AN, Pandian MR, Rojas FJ. Serum levels of androstenedione, testosterone and dehydroepiandrosterone sulfate in patients with premature ovarian failure to age-matched menstruating controls. Gynecol Obstet Invest. 1997;43(1):47–48. doi: https://doi.org/10.1159/000291817; Kalantaridou SN, Braddock DT, Patronas NJ, Nelson LM. Treatment of autoimmune premature ovarian failure. Hum Reprod. 1999;14(7):1777–1782. doi: https://doi.org/10.1093/humrep/14.7.1777; Чернуха Г.Е., Якушевская О.В. Овариальные эффекты витамина D: систематический обзор // Медицинский совет. — 2021. — № 3. — С. 44–49. — doi: https://doi.org/10.21518/2079701X-2021-3-44-49; Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Ross AC, Taylor CL, Yaktine AL, Del Valle HB, eds. Washington (DC): National Academies Press (US); 2011. doi: https://doi.org/10.17226/13050; Ling L, Feng X, Wei T, et al. Effects of low-intensity pulsed ultrasound (LIPUS)-pretreated human amnion-derived mesenchymal stem cell (hAD-MSC) transplantation on primary ovarian insufficiency in rats. Stem Cell Res Ther. 2017;8:283. doi: https://doi.org/10.1186/s13287-017-0739-3; Адамян Л.В., Сибирская Е.В., Щерина А.В. Патогенетические аспекты преждевременной недостаточности яичников // Проблемы репродукции. — 2021. — Т. 27. — № 1. — С. 6–12. — doi: https://doi.org/10.17116/repro2021270116; Na J, Kim GJ. Recent trends in stem cell therapy for premature ovarian insufficiency and its therapeutic potential: a review.j Ovarian Res. 2020;13(1):74. doi: https://doi.org/10.1186/s13048-02000671-2; Edessy M, Hosni HN, Shady Y, et al. Autologous stem cells therapy, the first baby of idiopathic premature ovarian failure. AMI. 2016;3(1):19–23. doi: https://doi.org/10.5530/ami.2016.1.7; Кумыкова З.Х., Батырова З.К., Уварова Е.В. Преждевременная недостаточность яичников в раннем репродуктивном возрасте: современные аспекты диагностики и ведения // Репродуктивное здоровье детей и подростков. — 2019. — Т. 15. — № 4. — С. 53–60. — doi: https://doi.org/10.24411/1816-2134-201914006.; https://www.pedpharma.ru/jour/article/view/2648

Availability: https://www.pedpharma.ru/jour/article/view/2648
https://doi.org/10.15690/pf.v22i3.2916

Challenges and solutions in sexual health among women after treatment for malignant neoplasms of the female reproductive system ; Проблемы и решения в области сексуального здоровья у женщин, перенесших лечение злокачественных новообразований женской репродуктивной системы

Authors: G. V. Dadalyan, A. A. Saakyan, S. D. Adamova, Kh. Kh. Alimkhanova, B. A. Aidaeva, N. M. Magomedova, A. R. Kabdegalieva, R. A. Besheeva, D. A. Osmanov, I. Z. Ersmurzaeva, I. A. Khalisov, S. U. Shafikova, F. R. Yaralieva, F. R. Gyulmagomedova, Г. В. Дадалян, А. А. Саакян, С. Д. Адамова, Х. Х. Алимханова, Б. А. Айдаева, Н. М. Магомедова, А. Р. Кабдегалиева, Р. А. Бешеева, Д. А. Османов, И. З. Эрсмурзаева, И. А. Халисов, С. У. Шафикова, Ф. Р. Яралиева, Ф. Р. Гюльмагомедова

Source: Obstetrics, Gynecology and Reproduction; Online First ; Акушерство, Гинекология и Репродукция; Online First ; 2500-3194 ; 2313-7347

Subject Terms: мультидисциплинарный подход, gynecologic cancer, quality of life, hormonal therapy, vaginal moisturizers, vaginal dilators, pelvic floor physical therapy, psychosocial counseling, access to healthcare, multidisciplinary approach, гинекологический рак, качество жизни, гормональная терапия, вагинальные увлажняющие средства, вагинальные расширители, физиотерапия тазового дна, психосоциальное консультирование, доступ к медицинской помощи

File Description: application/pdf

Relation: https://www.gynecology.su/jour/article/view/2482/1339; Шахзадова А.О., Старинский В.В., Лисичникова И.В. Состояние онкологической помощи населению России в 2022 году. Сибирский онкологический журнал. 2023;22(5):5–13. https://doi.org/10.21294/1814-4861-2023-22-5-5-13.; Авксентьев Н.A., Сисигина Н.H., Фролов М.Ю., Макаров А.C. Оценка вклада применения современных противоопухолевых лекарственных препаратов в достижение целей федерального проекта по борьбе с онкозаболеваниями. Вопросы онкологии. 2021;67(6):768–76. https://doi.org/10.37469/0507-3758-2021-67-6-768-776.; Siegel R.L., Kratzer T.B., Giaquinto A.N. et al. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10–45. https://doi.org/10.3322/caac.21871.; Sopfe J., Pettigrew J., Afghahi A. et al. Interventions to improve sexual health in women living with and surviving cancer: review and recommendations. Cancers (Basel). 2021;13(13):3153. https://doi.org/10.3390/cancers13133153.; Солопова А.Г., Санджиева Л.Н., Галкин В.Н. и др. Восстановление сексуальной функции после хирургического лечения рака эндометрия. Реабилитология. 2024;2(2):177–85. https://doi.org/10.17749/2949-5873/rehabil.2024.11.; Jing L., Zhang C., Li W. et al. Incidence and severity of sexual dysfunction among women with breast cancer: a meta-analysis based on female sexual function index. Support Care Cancer. 2019;27(4):1171–80. https://doi.org/10.1007/s00520-019-04667-7.; Кедрова А.Г. Возможности сохранения здоровья влагалища после лечения опухолей женской репродуктивной системы. Опухоли женской репродуктивной системы. 2022;18(4):121–6. https://doi.org/10.17650/1994-4098-2022-18-4-121-126.; Кондратьева К.O., Семиглазова Т.Ю., Каспаров Б.С. и др. Особенности сексуальности женщин после лечения рака молочной железы. Вопросы онкологии. 2023;69(1):108–14. https://doi.org/10.37469/0507-3758-2023-69-1-108-114.; Robison K., Kulkarni A., Dizon D.S. Sexual health in women affected by gynecologic or breast cancer. Obstet Gynecol. 2024;143(4):499–514. https://doi.org/10.1097/AOG.0000000000005506.; Канорский С.Г. Сексуальная дисфункция у мужчин и женщин с артериальной гипертензией. Южно-Российский журнал терапевтической практики. 2024;5(2):17–28. https://doi.org/10.21886/2712-8156-2024-5-2-17-28.; Sungur M.Z., Gündüz A. A comparison of DSM-IV-TR and DSM-5 definitions for sexual dysfunctions: critiques and challenges. J Sex Med. 2014;11(2):364–73. https://doi.org/10.1111/jsm.12379.; Reed M.A. Female sexual dysfunction. Clin Plast Surg. 2022;49(4):495–504. https://doi.org/10.1016/j.cps.2022.06.009.; Fausto D.Y., Martins J.B.B, da Silveira J. et al. Association between menopausal symptoms, sexual function, and sexual activity – a cross-sectional study. Prz Menopauzalny. 2023;22(4):220–6. https://doi.org/10.5114/pm.2023.133570.; Mundhra R., Bahadur A., Khoiwal K. et al. Female sexuality across the menopausal age group: a cross sectional study. Eur J Obstet Gynecol Reprod Biol X. 2024;21:100287. https://doi.org/10.1016/j.eurox.2024.100287.; Ahmed M.R., Shaaban M.M., Meky H.K. Assessment of sexually related personal distress accompanying premenopausal sexual dysfunction with an Arabic version of the Female Sexual Distress Scale. Int J Gynaecol Obstet. 2017;139(1):65–70. https://doi.org/10.1002/ijgo.12255.; Carter J., Lacchetti C., Andersen B.L. et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. J Clin Oncol. 2018;36(5):492–511. https://doi.org/10.1200/JCO.2017.75.8995.; Wiggins D.L., Wood R., Granai C.O., Dizon D.S. Sex, intimacy, and the gynecologic oncologists: survey results of the New England Association of Gynecologic Oncologists (NEAGO). J Psychosoc Oncol. 2007;25(4):61–70. https://doi.org/10.1300/J077v25n04_04.; Kennedy V., Abramsohn E., Makelarski J. et al. Can you ask? We just did! Assessing sexual function and concerns in patients presenting for initial gynecologic oncology consultation. Gynecol Oncol. 2015;137(1):119–24. https://doi.org/10.1016/j.ygyno.2015.01.451.; Sanft T., Day A., Ansbaugh S. et al. NCCN Guidelines® Insights: Survivorship, Version 1.2023. J Natl Compr Canc Netw. 2023;21(8):792–803. https://doi.org/10.6004/jnccn.2023.0041.; Sopfe J., Marsh R., Ziniel S.I. et al. Evaluation of the v2.0 brief profiles for sexual function and satisfaction PROMIS in adolescent and young adult childhood cancer survivors. J Adolesc Young Adult Oncol. 2021;10(4):418–24. https://doi.org/10.1089/jayao.2020.0166.; Polter E.J., Kohli N., Rosser B.R.S. et al. Creation and psychometric validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients – the Restore-2 Study. J Sex Med. 2022;19(3):529–40. https://doi.org/10.1016/j.jsxm.2021.12.012.; Greimel E., Nagele E., Lanceley A. et al. EORTC Quality of Life Group. Psychometric validation of the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire Sexual Health (EORTC QLQ-SH22). Eur J Cancer. 2021;154:235–45. https://doi.org/10.1016/j.ejca.2021.06.003.; Идрисова Л.Э., Солопова А.Г., Макацария А.Д. и др. Возможности восстановления сексуальной функции у женщин после лечения рака молочной железы. Врач. 2018;29(4):64–7. https://doi.org/10.29296/258773052018-04-13.; Lindau S.T., Gavrilova N., Anderson D. Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. Gynecol Oncol. 2007;106(2):413–8. https://doi.org/10.1016/j.ygyno.2007.05.017.; Green M.S., Naumann R.W., Elliot M. et al. Sexual dysfunction following vulvectomy. Gynecol Oncol. 2000;77(1):73–7. https://doi.org/10.1006/gyno.2000.5745.; Подзолкова Н.М., Колода Ю.А., Никитина Т.И. Лапароскопическая гистерэктомия: влияние на сексуальную функцию. Проблемы репродукции. 2012;(6):60–2.; Pak R., Sadykova T., Kaidarova D. et al. The life quality and sexual function of women underwent radical hysterectomy. Asian Pac J Cancer Prev. 2021;22(2):581–9. https://doi.org/10.31557/APJCP.2021.22.2.581.; Pieterse Q.D., Maas C.P., ter Kuile M.M. et al. An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. Int J Gynecol Cancer. 2006;16(3):1119–29. https://doi.org/10.1111/j.1525-1438.2006.00461.x.; Maas C.P., ter Kuile M.M., Laan E. et al. Objective assessment of sexual arousal in women with a history of hysterectomy. BJOG. 2004;111(5):456–62. https://doi.org/10.1111/j.1471-0528.2004.00104.x.; Plante M., Kwon J.S., Ferguson S. et al. Simple versus radical hysterectomy in women with low-risk cervical cancer. N Engl J Med. 2024;390(9):819–29. https://doi.org/10.1056/NEJMoa2308900.; Мухин А.А., Важенин А.В., Саевец В.В., Таратонов А.В. Хирургическое лечение местно-распространенного рака вульвы. Злокачественные опухоли. 2020;10(3):20–5. https://doi.org/10.18027/2224-5057-2020-10-3-20-25.; Flynn K.E., Carter J., Lin L. et al. Assessment of vulvar discomfort with sexual activity among women in the United States. Am J Obstet Gynecol. 2017;216(4):391.e1–391.e8. https://doi.org/10.1016/j.ajog.2016.12.006.; Likes W.M., Stegbauer C., Tillmanns T., Pruett J. Correlates of sexual function following vulvar excision. Gynecol Oncol. 2007;105(3):600–3. https://doi.org/10.1016/j.ygyno.2007.01.027.; Barlow E.L., Hacker N.F., Hussain R., Parmenter G. Sexuality and body image following treatment for early-stage vulvar cancer: a qualitative study. J Adv Nurs. 2014;70(8):1856–66. https://doi.org/10.1111/jan.12346.; Günther V., Malchow .B, Schubert M. et al. Impact of radical operative treatment on the quality of life in women with vulvar cancer--a retrospective study. Eur J Surg Oncol. 2014;40(7):875–82. https://doi.org/10.1016/j.ejso.2014.03.027.; Сибирская Е.В., Никифорова П.О., Рабаданова Н.Р. Первичная циторедуктивная хирургия с последующей химиотерапией в сравнении с неоадъювантной химиотерапией с последующей циторедукцией в качестве лечения III и IV стадий рака яичника (обзор литературы). Опухоли женской репродуктивной системы. 2024;20(1):124–30. https://doi.org/10.17650/1994-4098-2024-20-1-124-130.; Hughes C.L., Wall L.L., Creasman W.T. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol Oncol. 1991;40(1):42–5. https://doi.org/10.1016/0090-8258(91)90083-h.; Блинов Д.В., Солопова А.Г., Ачкасов Е.Е. и др. Организация реабилитации пациенток с опухолями яичников: современные подходы и будущие направления. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2023;16(2):303–16. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.196.; Yoshida K., Yamazaki H., Nakamura S. et al. Longitudinal analysis of late vaginal mucosal reactions after high-dose-rate brachytherapy in patients with gynecological cancer. Anticancer Res. 2014;34(8):4433–8.; Charatsi D., Vanakara P., Evaggelopoulou E. et al. Vaginal dilator use to promote sexual wellbeing after radiotherapy in gynecological cancer survivors. Medicine (Baltimore). 2022;101(4):e28705. https://doi.org/10.1097/MD.0000000000028705.; Rovirosa Á., Ascaso C., Herreros A. et al. A new short daily brachytherapy schedule in postoperative endometrial carcinoma. Preliminary results. Brachytherapy. 2017;16(1):147–52. https://doi.org/10.1016/j.brachy.2016.10.001.; Hill-Kayser C., Yorke E., Jackson A. et al. Effects of radiation therapy on the female reproductive tract in childhood cancer survivors: a PENTEC comprehensive Review. Int J Radiat Oncol Biol Phys. 2024;119(2):588–609. https://doi.org/10.1016/j.ijrobp.2023.08.013.; Derks M., van Lonkhuijzen L.R., Bakker R.M. et al. Long-term morbidity and quality of life in cervical cancer survivors: a multicenter comparison between surgery and radiotherapy as primary treatment. Int J Gynecol Cancer. 2017;27(2):350–6. https://doi.org/10.1097/IGC.0000000000000880.; Maiorino M.I., Chiodini P., Bellastella G. et al. Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index. Endocrine. 2016;54(2):329–41. https://doi.org/10.1007/s12020-015-0812-6.; Liavaag A.H., Dørum A., Bjøro T. et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol. 2008;108(2):348–54. https://doi.org/10.1016/j.ygyno.2007.10.009.; Wu X., Wu L., Han J. et al. Evaluation of the sexual quality of life and sexual function of cervical cancer survivors after cancer treatment: a retrospective trial. Arch Gynecol Obstet. 2021;304(4):999–1006. https://doi.org/10.1007/s00404-021-06005-x.; Kulkarni A., Sun G., Manuppelli S. et al. Sexual health and function among patients receiving systemic therapy for primary gynecologic cancers. Gynecol Oncol. 2022;165(2):323–29. https://doi.org/10.1016/j.ygyno.2022.03.008.; Whicker M., Black J., Altwerger G. et al. Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer. Am J Obstet Gynecol. 2017;217(4):395–403. https://doi.org/10.1016/j.ajog.2017.04.012.; Rowland J.H., Meyerowitz B.E., Crespi C.M. et al. Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention. Breast Cancer Res Treat. 2009;118(1):99–111. https://doi.org/10.1007/s10549-009-0398-x.; Kalaitzi C., Papadopoulos V.P., Michas K. et al. Combined brief psychosexual intervention after mastectomy: effects on sexuality, body image, and psychological well-being. J Surg Oncol. 2007;96(3):235–40. https://doi.org/10.1002/jso.20811.; Андреева Е.Н., Шереметьева Е.В. Проблема женской сексуальности. Проблемы репродукции. 2019;25(3):40–50. https://doi.org/10.17116/repro20192503140.; Ratner E.S., Foran K.A., Schwartz P.E., Minkin M.J. Sexuality and intimacy after gynecological cancer. Maturitas. 2010;66(1):23–6. https://doi.org/10.1016/j.maturitas.2010.01.015.; Simon J.A., Thorp J., Millheiser L. Flibanserin for premenopausal hypoactive sexual desire Disorder: pooled analysis of clinical trials. J Womens Health (Larchmt). 2019;28(6):769–77. https://doi.org/10.1089/jwh.2018.7516.; Kamrul-Hasan A.B.M., Hannan M.A., Alam M.S. et al. Role of flibanserin in managing hypoactive sexual desire disorder in women: a systematic review and meta-analysis. Medicine (Baltimore). 2024;103(25):e38592. https://doi.org/10.1097/MD.0000000000038592.; Simon J.A., Kingsberg S.A., Shumel B. et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633–40. https://doi.org/10.1097/GME.0000000000000134.; Goldfarb S.B., Carter J., Arkema A. et al. Effect of flibanserin on libido in women with breast cancer on adjuvant endocrine therapy. J Clin Oncol. 2023;41(16):12015. https://doi.org/10.1200/JCO.2023.41.16_suppl.12015.; Shaukat A., Mujeeb A., Shahnoor S. et al. "Veozah (Fezolinetant): a promising non-hormonal treatment for vasomotor symptoms in menopause". Health Sci Rep. 2023;6(10):e1610. https://doi.org/10.1002/hsr2.1610.; Рафаэлян И.В., Балан В.Е., Ковалева Л.А. Фитоэстрогены: что известно на сегодняшний день. Акушерство и гинекология. 2012;(5):4–9.; Балан В.Е., Рафаэлян И.В., Левкович Е.А. и др. Особенности длительного применения фитоэстрогенов для лечения пациенток с климактерическим синдромом. Российский вестник акушера-гинеколога. 2013;13(5):58–62.; Goetsch M.F., Lim J.Y., Caughey A.B. A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial. J Clin Oncol. 2015;33(30):3394–400. https://doi.org/10.1200/JCO.2014.60.7366.; “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–94. https://doi.org/10.1097/GME.0000000000002028.; Бабаева Н.А., Юренева С.В., Алешикова О.И. и др. Возможности использования гормональной терапии у больных, перенесших лечение по поводу злокачественных новообразований вульвы, влагалища, шейки и тела матки. Онкология. Журнал имени П.А. Герцена. 2023;12(1):45–52. https://doi.org/10.17116/onkolog20231201145.; Назаренко Т.А., Пароконная А.А., Шарипова Н.Ю. Применение ингибиторов ароматазы у больных раком молочной железы в программах вспомогательных репродуктивных технологий. Проблемы репродукции. 2012;(2):72–6.; Шляхто Е.В., Сухих Г.Т., Серов В.Н. и др. Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ РКО, РОАГ, РАЭ, ЕАТ, РАФ. Проблемы эндокринологии. 2023;69(5):115–36. https://doi.org/10.14341/probl1339.; Santen R.J. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015;18(2):121–34. https://doi.org/10.3109/13697137.2014.947254.; Manson J.E., Chlebowski R.T., Stefanick M.L. et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353–68. https://doi.org/10.1001/jama.2013.278040.; Якушевская О.В., Юренева С.В., Хабас Г.Н., Протасова А.Э. Менопаузальная гормональная терапия и рак шейки матки: современный взгляд на проблему. Акушерство и гинекология. 2017;(11):148–53. https://doi.org/10.18565/aig.2017.11.148-153.; Якушевская О.В., Аверкова В.Г., Юренева С.В. Отягощенный онкологический анамнез и климактерические расстройства: помочь нельзя мириться. Медицинский совет. 2025;(4):151–9. https://doi.org/10.21518/ms2025-169.; Barakat R.R., Bundy B.N., Spirtos N.M. et al Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(4):587–92. https://doi.org/10.1200/JCO.2005.02.8464.; Pergialiotis V., Pitsouni E., Prodromidou A. et al. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause. 2016;23(3):335–42. https://doi.org/10.1097/GME.0000000000000508.; Бейшембаев А.М. Особенности лечения редких форм стромально-клеточных опухолей яичников: серия клинических наблюдений. Тазовая хирургия и онкология. 2021;11(1):28–34. https://doi.org/10.17650/2686-9594-2021-11-1-28-34.; Achimaș-Cadariu P.A., Păun D.L., Pașca A. Impact of hormone replacement therapy on the overall survival and progression free survival of ovarian cancer patients: a systematic review and meta-analysis. Cancers (Basel). 2023;15(2):356. https://doi.org/10.3390/cancers15020356.; Abu-Rustum N.R., Yashar C.M., Arend R. et al. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. J Natl Compr Canc Netw. 2023;21(12):1224–33. https://doi.org/10.6004/jnccn.2023.0062.; Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol Oncol. 1987;26(2):169–77. https://doi.org/10.1016/0090-8258(87)90270-8.; Lacey J.V., Brinton L.A., Barnes W.A. et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol. 2000;77(1):149–54. https://doi.org/10.1006/gyno.2000.5731.; Лушникова П.А., Сухих Е.С., Ижевский П.В. и др. Современные методы лучевой терапии рака шейки матки. Креативная хирургия и онкология. 2021;11(1):58–67. https://doi.org/10.24060/2076-3093-2021-11-1-58-67.; Дикке Г.Б., Остроменский В.В., Щербатых Е.Ю. Влагалищные дилататоры в профилактике и лечении стеноза и болевых синдромов влагалища. Акушерство и гинекология. 2023;(12):181–8. https://doi.org/10.18565/aig.2023.296.; Quinn B.A., Deng X., Sullivan S.A. et al. Change in vaginal length and sexual function in women who undergo surgery ± radiation therapy for endometrial cancer. Brachytherapy. 2023;22(3):334–42. https://doi.org/10.1016/j.brachy.2023.01.005.; Liu M., Juravic M., Mazza G., Krychman M.L. Vaginal dilators: issues and answers. Sex Med Rev. 2021;9(2):212–20. https://doi.org/10.1016/j.sxmr.2019.11.005.; Barbera L., Zwaal C., Elterman D. et al.; Interventions to Address Sexual Problems in People with Cancer Guideline Development Group. Interventions to address sexual problems in people with cancer. Curr Oncol. 2017;24(3):192–200. https://doi.org/10.3747/co.24.3583.; Аполихина И.А., Родионов В.В., Сеялова А.С. и др. Тренировка мышц тазового дна у женщин, перенесших рак молочных желез. Гинекология. 2019;21(1):9–22. https://doi.org/10.26442/20795696.2019.1.190229.; Cyr M.P., Dostie R., Camden C. et al. Acceptability of multimodal pelvic floor physical therapy to treat dyspareunia after gynecological malignancies: a qualitative study of women's views and experiences. Int Urogynecol J. 2023;34(5):1061–73. https://doi.org/10.1007/s00192-022-05304-4.; Cyr M.P., Dostie R., Camden C. et al. Improvements following multimodal pelvic floor physical therapy in gynecological cancer survivors suffering from pain during sexual intercourse: results from a one-year follow-up mixed-method study. PLoS One. 2022;17(1):e0262844. https://doi.org/10.1371/journal.pone.0262844.; Чернова Н.И., Доля О.В., Фриго Н.В., Задорожная И.С. Увлажняющие средства при ведении пациенток с жалобами на сухость в области гениталий. Акушерство и гинекология. 2024;(8):134–40. https://doi.org/10.18565/aig.2024.198.; Edwards D., Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19(2):151–61. https://doi.org/10.3109/13697137.2015.1124259.; Juraskova I., Jarvis S., Mok K. et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J Sex Med. 2013;10(10):2549–58. https://doi.org/10.1111/jsm.12156.; Стеняева Н.Н., Саттарова В.В., Пашкевич К.И. и др. Вагинальные любриканты: эффективность, переносимость, безопасность и функциональность. Акушерство и гинекология. 2023;(8):203–10. https://doi.org/10.18565/aig.2023.179.; Herbenick D., Reece M., Hensel D. et al. Association of lubricant use with women's sexual pleasure, sexual satisfaction, and genital symptoms: a prospective daily diary study. J Sex Med. 2011;8(1):202–12. https://doi.org/10.1111/j.1743-6109.2010.02067.x.; Pérez-López F.R., Phillips N., Vieira-Baptista P. et al. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease. Gynecol Endocrinol. 2021;37(8):746–2. https://doi.org/10.1080/09513590.2021.1943346.; Лосева Н.В., Ярославцева И.В. Особенности психологического консультирования женщин с нарушением репродуктивной функции. Acta Biomedica Scientifica. 2014;(4):96–9.; Самушия М.А. Психические расстройства у пациенток со злокачественными опухолями органов женской репродуктивной системы: обзор литературы. Опухоли женской репродуктивной системы. 2011;(1):86–95. https://doi.org/10.17650/1994-4098-2011-0-1-216-241.; Санджиева Л.Н., Солопова А.Г., Блинов Д.В. и др. Персонифицированная программа комплексной реабилитации после хирургического лечения рака эндометрия: результаты проспективного рандомизированного сравнительного исследования. Акушерство, Гинекология и Репродукция. 2022;16(2):143–57. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.318.; Тювина Н.А., Балабанова В.В., Воронина Е.О. Депрессии у женщин, манифестирующие в период климактерия. Журнал неврологии и психиатрии имени С.С. Корсакова. 2017;117(3):22–7. https://doi.org/10.17116/jnevro20171173122-27.; https://www.gynecology.su/jour/article/view/2482

Availability: https://www.gynecology.su/jour/article/view/2482
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2025.643

An exposition on complete androgen insensitivity syndrome and a case report ; Синдром полной нечувствительности к андрогенам: клинический случай

Authors: S. Morkos, M. Al Qasem, M. Aldam, H. K. Bhotla, A. Meyyazhagan, M. Pappuswamy, F. Iskandarani, K. Kouteich, A. Asoliman, С. Моркос, М. Аль-Касем, М. Алдам, Х. К. Бхотла, А. Мейяжаган, М. Паппусвами, Ф. Искандарани, Х. Кутейч, А. Асолиман

Source: Obstetrics, Gynecology and Reproduction; Vol 19, No 1 (2025); 127-135 ; Акушерство, Гинекология и Репродукция; Vol 19, No 1 (2025); 127-135 ; 2500-3194 ; 2313-7347

Subject Terms: клинический случай, CAIS, XY, gonads, androgen receptor, AR, hormone replacement therapy, case report, СПНкА, гонады, рецептор андрогенов, РА, заместительная гормональная терапия

Time: 46

File Description: application/pdf

Relation: https://www.gynecology.su/jour/article/view/2349/1303; Hughes I.A., Houk C., Ahmed S.F., Lee P.A.; LWPES Consensus Group; ESPE Consensus Group. Consensus statement on management of intersex disorders. Arch Dis Child. 2006;91(7):554–63. https://doi.org/10.1136/adc.2006.098319.; Delli Paoli E., Di Chiano S., Paoli D. et al. Androgen insensitivity syndrome: a review. J Endocrinol Invest. 2023;46(11):2237–45. https://doi.org/10.1007/s40618-023-02127-y.; Hughes I.A., Davies J.D., Bunch T.I. et al. Androgen insensitivity syndrome. Lancet. 2012;380(9851):1419–28. https://doi.org/10.1016/S0140-6736(12)60071-3.; Costagliola G., di Cosci M.C.O., Masini B. et al. Disorders of sexual development with XY karyotype and female phenotype: clinical findings and genetic background in a cohort from a single centre. J Endocrinol Invest. 2021;44(1):145–51. https://doi.org/10.1007/s40618-020-01284-8.; Peng Y., Zhu H., Han B. et al. Identification of potential genes in pathogenesis and diagnostic value analysis of partial androgen Insensitivity syndrome using bBioinformatics analysis. Front Endocrinol. 2021;12:731107. https://doi.org/10.3389/fendo.2021.731107.; Morris J.M. The syndrome of testicular feminization in male pseudohermaphrodites. Am J Obstet Gynecol. 1953;65(6):1192–211. https://doi.org/10.1016/0002-9378(53)90359-7.; Brown C.J., Goss S.J., Lubahn D.B. et al. Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet. 1989;44(2):264–9.; Brown T.R., Lubahn D.B., Wilson E.M. et al. Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: evidence for further genetic heterogeneity in this syndrome. Proc Natl Acad Sci U S A. 1988;85(21):8151–5. https://doi.org/10.1073/pnas.85.21.8151.; Quigley C.A., De Bellis A., Marschke K.B. et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev. 1995;16(3):271–321. https://doi.org/10.1210/edrv-16-3-271.; Melo K.F.S., Mendonca B.B., Billerbeck A.E. et al. Clinical, hormonal, behavioral, and genetic characteristics of androgen insensitivity syndrome in a Brazilian cohort: five novel mutations in the androgen receptor gene. J Clin Endocrinol Metab. 2003;88(7):3241–50. https://doi.org/10.1210/jc.2002-021658.; Pinsky L., Kaufman M., Killinger D.W. et al. Human minimal androgen insensitivity with normal dihydrotestosterone-binding capacity in cultured genital skin fibroblasts: evidence for an androgen-selective qualitative abnormality of the receptor. Am J Hum Genet. 1984;36(5):965–78.; Pizzo A., Laganà A.S., Borrielli I., Dugo N. Complete androgen insensitivity syndrome: a rare case of disorder of sex development. Case Rep Obstet Gynecol. 2013;2013:232696. https://doi.org/10.1155/2013/232696.; Oakes M.B., Eyvazzadeh A.D., Quint E., Smith Y.R. Complete androgen insensitivity syndrome – a review. J Pediatr Adolesc Gynecol. 2008;21(6):305–10. https://doi.org/10.1016/j.jpag.2007.09.006.; Stephens J.D. Prenatal diagnosis of testicular feminisation. Lancet. 1984;2(8410):1038. https://doi.org/10.1016/s0140-6736(84)91134-6.; Grumbach M.M., Conte F.A., Hughes I.A. Disorders of sex differentiation. In: Williams textbook of endocrinology. Eds. P.R. Larsen, H.M. Kronenberg, S. Melmed et al. 10th ed. Philadelphia: W.B. Saunders, 2002.; Singh S., Ilyayeva S. Androgen Insensitivity Syndrome. In: StatPearls. Treasure Island (FL), 2023 Feb 28.; Berglund A., Johannsen T.H., Stochholm K. et al. Incidence, Prevalence, diagnostic delay, and clinical presentation of female 46,XY disorders of sex development. J Clin Endocrinol Metab. 2016;101(12):4532–40. https://doi.org/10.1210/jc.2016-2248.; Boehmer A.L., Brinkmann O., Brüggenwirth H. et al. Genotype versus phenotype in families with androgen insensitivity syndrome. J Clin Endocrinol Metab. 2001;86(9):4151–60. https://doi.org/10.1210/jcem.86.9.7825.; Gulía C., Baldassarra S., Zangari A. et al. Androgen insensitivity syndrome. Eur Rev Med Pharmacol Sci. 2018;22(12):3873–87. https://doi.org/10.26355/eurrev_201806_15272.; Dey R., Biswas S.C., Chattopadhvav N. et al. The XY female (Androgen Insensitivity Syndrome)-runs in the family. J Obstet Gynaecol India. 2012;62(3):332–3. https://doi.org/10.1007/s13224-011-0112-x.; Batista R.L., Costa E.M.F., Rodrigues A.S. et al. Androgen insensitivity syndrome: a review. Arch Endocrinol Metab. 2018;62(2):227–35. https://doi.org/10.20945/2359-3997000000031.; Gottlieb B., Pinsky L., Beitel L.K., Trifiro M. Androgen insensitivity. Am J Med Genet. 1999;89(4):210–7. https://doi.org/10.1002/(sici)1096-8628(19991229)89:43.0.co;2-p.; Doehnert U., Bertelloni S., Werner R. et al. Characteristic features of reproductive hormone profiles in late adolescent and adult females with complete androgen insensitivity syndrome. Sex Dev. 2015;9(2):69–74. https://doi.org/10.1159/000371464.; Lanciotti L., Cofini M., Leonardi A. et al. Different clinicalpresentations and management in Complete Androgen Insensitivity Syndrome (CAIS). Int J Environ Res Public Health. 2019;16(7):1268. https://doi.org/10.3390/ijerph16071268.; Mainwaring W.I. The mechanism of action of androgens. Monogr Endocrinol. 1977;10:1–178.; Verhoeven G., Swinnen J.V. Indirect mechanisms and cascades of androgen action. Mol Cell Endocrinol. 1999;151(1–2):205–12. https://doi.org/10.1016/s0303-7207(99)00014-3.; Galani A., Kitsiou-Tzeli S., Sofokleous C. et al. Androgen insensitivity syndrome: clinical features and molecular defects. Hormones (Athens). 2008;7(3):217–29. https://doi.org/10.14310/horm.2002.1201.; Gobinet J., Poujol N., Sultan C. Molecular action of androgens. Mol Cell Endocrinol. 2002;198(1–2):15–24. https://doi.org/10.1016/s0303-7207(02)00364-7.; Tyutyusheva N., Mancini I., Baroncelli G.I. et al. Complete Androgen Insensitivity Syndrome: from bench to bed. Int J Mol Sci. 2021;22(3):1264. https://doi.org/10.3390/ijms22031264.; Hiort O., Sinnecker G.H., Holterhus P.M. et al. Inherited and de novo androgen receptor gene mutations: investigation of single-case families. J Pediatr. 1998;132(6):939–43. https://doi.org/10.1016/s0022-3476(98)70387-7.; Brown T.R. Human androgen insensitivity syndrome. J Androl. 1995;16(4):299–303.; Gelmann E.P. Androgen receptor mutations in prostate cancer. Cancer Treat Res. 1996;87:285–302. https://doi.org/10.1007/978-1-4613-1267-3_12.; Sack J.S., Kish K.F., Wang C. et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A. 2001;98(9):4904–9. https://doi.org/10.1073/pnas.081565498.; Lobaccaro J.M., Poujol N., Chiche L. et al. Molecular modeling and in vitro investigations of the human androgen receptor DNA-binding domain: application for the study of two mutations. Mol Cell Endocrinol. 1996;116(2):137–47. https://doi.org/10.1016/0303-7207(95)03709-8.; Brüggenwirth H.T., Boehmer A.L., Lobaccaro J.M. et al. Substitution of Ala564 in the first zinc cluster of the deoxyribonucleic acid (DNA)-binding domain of the androgen receptor by Asp, Asn, or Leu exerts differential effects on DNA binding. Endocrinology. 1998;139(1):103–10. https://doi.org/10.1210/endo.139.1.5696.; Greep R.O. Reproductive endocrinology: concepts and perspectives, an overview. Recent Prog Horm Res. 1978;34:1–23. https://doi.org/10.1016/b978-0-12-571134-0.50005-3.; Bouvattier C., Carel J.-C., Lecointre C. et al. Postnatal changes of T, LH, and FSH in 46,XY infants with mutations in the AR gene. J Clin Endocrinol Metab. 2002;87(1):29–32. https://doi.org/10.1210/jcem.87.1.7923.; Griffin J.E., Edwards C., Madden J.D. et al. Congenital absence of the vagina. The Mayer-Rokitansky-Kuster-Hauser syndrome. Ann Intern Med. 1976;85(2):224–36. https://doi.org/10.7326/0003-4819-85-2-224.; Hannema S.E., Scott I.S., Rajpert-De Meyts E. et al. Testicular development in the complete androgen insensitivity syndrome. J Pathol. 2006;208(4):518–27. https://doi.org/10.1002/path.1890.; Bertelloni S., Dati E., Baroncelli G.I., Hiort O. Hormonal management of complete androgen insensitivity syndrome from adolescence onward. Horm Res Paediatr. 2011;76(6):428–33. https://doi.org/10.1159/000334162.; Birnbaum W., Bertelloni S. Sex hormone replacement in disorders of sex development. Endocr Dev. 2014;27:149–59. https://doi.org/10.1159/000363640.; Reddy D.S. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol. Neuroscience. 2004;129(1):195–207. https://doi.org/10.1016/j.neuroscience.2004.08.002.; Auer M.K., Birnbaum W., Hartmann M.F. et al. Metabolic effects of estradiol versus testosterone in complete androgen insensitivity syndrome. Endocrine. 2022;76(3):722–32. https://doi.org/10.1007/s12020-022-03017-8.; Poujol N., Lobaccaro J.M., Chiche L. et al. Functional and structural analysis of R607Q and R608K androgen receptor substitutions associated with male breast cancer. Mol Cell Endocrinol. 1997;130(1–2):43–51. https://doi.org/10.1016/s0303-7207(97)00072-5.; Coutant R., de Casson F.B., Rouleau S. et al. Divergent effect of endogenous and exogenous sex steroids on the insulin-like growth factor I response to growth hormone in short normal adolescents. J Clin Endocrinol Metab. 2004;89(12):6185–92. https://doi.org/10.1210/jc.2004-0814.; Perry R.J., Farquharson C., Ahmed S.F. The role of sex steroids in controlling pubertal growth. Clin Endocrinol (Oxf). 2008;68(1):4–15. https://doi.org/10.1111/j.1365-2265.2007.02960.x.; Ferlin A., Selice R., Carraro U., Foresta C. Testicular function and bone metabolism – beyond testosterone. Nat Rev Endocrinol. 2013;9(9):548– 54. https://doi.org/10.1038/nrendo.2013.135.; Döhnert U., Wünsch L., Hiort O. Gonadectomy in Complete Androgen Insensitivity Syndrome: why and when? Sex Dev. 2017;11(4):171–4. https://doi.org/10.1159/000478082.; Tack L.J.W., Maris E., Looijenga L.H.J. et al. Management of gonads in adults with androgen insensitivity: an International Survey. Horm Res Paediatr. 2018;90(4):236–46. https://doi.org/10.1159/000493645.; Lucas-Herald A., Bertelloni S., Juul A. et al. The long-term outcome of boys with Partial Androgen Insensitivity Syndrome and a mutation in the androgen receptor gene. J Clin Endocrinol Metab. 2016;101(11):3959–67. https://doi.org/10.1210/jc.2016-1372.; Bouvattier C., Mignot B., Lefèvre H. et al. Impaired sexual activity in male adults with partial androgen insensitivity. J Clin Endocrinol Metab. 2006;91(9):3310–5. https://doi.org/10.1210/jc.2006-0218.; Rasheed M.W., Idowu N.A., Adekunle A.A. et al. Complete androgen insensitivity syndrome with Sertoli cell tumour in a 27-year-old married woman: a case report. Afr J Urol. 2023;29(1):26. https://doi.org/10.1186/s12301-023-00358-2.; Hughes I.A., Deeb A. Androgen resistance. Best Pract Res Clin Endocrinol Metab. 2006;20(4):577–98. https://doi.org/10.1016/j.beem.2006.11.003.; GeneReviews®. Eds. M.P. Adam, J. Feldman, G.M. Mirzaa et al. Seattle (WA): University of Washington, Seattle, 1993. Copyright© 1993–2024.; Healey A. Embryology of the female reproductive tract. In: Imaging of gynecological disorders in infants and children. Eds. G.S. Mann, J.C. Blair, A.S. Garden. Springer Berlin, Heidelberg, 2012. 21–30. https://doi.org/10.1007/978-3-540-85602-3.; Valappil S., Chetan U., Wood N., Garden A. Mayer–Rokitansky–Küster–Hauser syndrome: diagnosis and management. The Obstetrician & Gynaecologist. 2012;14(2):93–8. https://doi.org/10.1111/j.1744-4667.2012.00097.x.; Cools M., Looijenga L. Update on the pathophysiology and risk factors for the development of malignant testicular germ cell tumors in Complete Androgen Insensitivity Syndrome. Sex Dev. 2017;11(4):175–81. https://doi.org/10.1159/000477921.; Chaudhry S., Tadokoro-Cuccaro R., Hannema S.E. et al. Frequency of gonadal tumours in complete androgen insensitivity syndrome (CAIS): A retrospective case-series analysis. J Pediatr Urol. 2017;13(5):498. e1–498.e6. https://doi.org/10.1016/j.jpurol.2017.02.013.; https://www.gynecology.su/jour/article/view/2349

Availability: https://www.gynecology.su/jour/article/view/2349
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2025.539

Hormone Replacement Therapy and Health of Postmenopausal Women

Source: Труды НИИСИ РАН. 12:38-46

Subject Terms: минеральная плотность костной ткани, остеопения, анализ данных, менопауза, постменопауза, медицинская информатика, остеопороз, статистическая проверка гипотез, денситометрия, заместительная гормональная терапия, 3. Good health

ПРЕДУПРЕЖДЕНИЕ ПОТЕНЦИАЛЬНЫХ ПОБОЧНЫХ ЭФФЕКТОВ ЗАМЕСТИТЕЛЬНОЙ ГОРМОНАЛЬНОЙ ТЕРАПИИ В ГЕНЕТИЧЕСКИХ ДАННЫХ

Subject Terms: Заместительная гормональная терапия, климактерический синдром, генетические факторы, персонализированная медицина

ПРЕДУПРЕЖДЕНИЕ ПОТЕНЦИАЛЬНЫХ ПОБОЧНЫХ ЭФФЕКТОВ ЗАМЕСТИТЕЛЬНОЙ ГОРМОНАЛЬНОЙ ТЕРАПИИ В ГЕНЕТИЧЕСКИХ ДАННЫХ

Subject Terms: Заместительная гормональная терапия, климактерический синдром, генетические факторы, персонализированная медицина

Проблемы перехода с циклической менопаузальной гормональной терапии на непрерывную комбинированную у женщин в постменопаузе ; Challenges of switching from cyclic menopausal hormone therapy to continuous combination therapy in postmenopausal women

Authors: Edilova, K. I., Gileva, V. A., Guzhavina, P. A., Zvychainyi, M. A., Vorontsova, A. V., Эдилова, Х. И., Гилева, В. А., Гужавина, П. А., Звычайный, М. А., Воронцова, А. В.

Source: Сборник статей

Subject Terms: CYCLIC MENOPAUSAL HORMONE THERAPY, CONTINUOUS COMBINED MENOPAUSAL HORMONE THERAPY, POSTMENOPAUSE, ЦИКЛИЧЕСКАЯ МЕНОПАУЗАЛЬНАЯ ГОРМОНАЛЬНАЯ ТЕРАПИЯ, НЕПРЕРЫВНАЯ КОМБИНИРОВАННАЯ МЕНОПАУЗАЛЬНАЯ ГОРМОНАЛЬНАЯ ТЕРАПИЯ, ПОСТМЕНОПАУЗА

File Description: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения : Сборник статей IX Международной научно-практической конференции молодых ученых и студентов, 17-18 апреля 2024 г. Т. 1.; http://elib.usma.ru/handle/usma/21122

Availability: http://elib.usma.ru/handle/usma/21122

ЛЕЧЕНИЕ НЕОБСТРУКТИВНОЙ АЗООСПЕРМИИ С ПОМОЩЬЮ МЕЗЕНХИМАЛЬНЫХ СТВОЛОВЫХ КЛЕТОК. КЛИНИЧЕСКИЙ СЛУЧАЙ: TREATMENT OF NON-OBSTRUCTIVE AZOOSPERMIA WITH MESENCHYMAL STEM CELLS. CLINICAL CASE.

Source: Наука и здравоохранение. :240-245

Subject Terms: мужское бесплодие, mesenchymal stem cells, hormonal therapy, мезенхималықдің жасушалары, необструктивная азооспермия, male infertility, 3. Good health, клеточная терапия, гормональная терапия, жасушалық терапия, гормондық терапия, non-obstructive azoospermia, ербедеулігі, cell therapy, мезенхимальные стволовые клетки, обструктивті емес азооспермия

Вопросы клиники бешенства и неврологических осложнений при применении антирабических прививок

Authors: Алиева, Р.А.

Source: Science and Education; Vol. 5 No. 9 (2024): Science and Education; 98-104 ; 2181-0842

Subject Terms: бешенство, паралич Ландри, вирус, антирабическая вакцина, гормональная терапия

File Description: application/pdf

Relation: https://openscience.uz/index.php/sciedu/article/view/7184/6577; https://openscience.uz/index.php/sciedu/article/view/7184

Availability: https://openscience.uz/index.php/sciedu/article/view/7184

Female magnesium deficiency and its management: review of current knowledge ; Дефицит магния у женщин и его контроль: обзор современных представлений

Authors: A. D. Makatsariya, V. O. Bitsadze, A. G. Solopova, O. A. Gromova, D. I. Korabelnikov, D. V. Blinov, J. Kh. Khizroeva, N. A. Makatsariya, M. V. Tretyakova, S. A. Akavova, D. M. Ampilogova, А. Д. Макацария, В. О. Бицадзе, А. Г. Солопова, О. А. Громова, Д. И. Корабельников, Д. В. Блинов, Д. Х. Хизроева, Н. А. Макацария, М. В. Третьякова, С. А. Акавова, Д. М. Ампилогова

Contributors: The work was financially supported by Sanofi pharmaceutical company, Работа выполнена при финансовой поддержке фармацевтической компании Санофи

Source: Obstetrics, Gynecology and Reproduction; Vol 18, No 2 (2024); 218-230 ; Акушерство, Гинекология и Репродукция; Vol 18, No 2 (2024); 218-230 ; 2500-3194 ; 2313-7347

Subject Terms: витамин B 6, magnesium deficiency, dysmenorrhea, premenstrual syndrome, PMS, polycystic ovarian syndrome, POS, menopause, climacteric syndrome, osteoporosis, oral combined oral contraceptives, COCs, menopausal hormone therapy, MHT, magnesium citrate, pyridoxine, vitamin B 6, дефицит магния, дисменорея, предменструальный синдром, ПМС, синдром поликистозных яичников, СПКЯ, климакс, климактерический синдром, остеопороз, комбинированные оральные контрацептивы, КОК, менопаузальная гормональная терапия, МГТ

File Description: application/pdf

Relation: https://www.gynecology.su/jour/article/view/2053/1202; Grober U., Schmidt J., Kisters K. Magnesium in prevention and therapy. Nutrients. 2015;7(9):8199–226. doi:10.3390/nu7095388.; Bertinato J., Wu Xiao C., Ratnayake W.M. et al. Lower serum magnesium concentration is associated with diabetes, insulin resistance, and obesity in South Asian and white Canadian women but not men. Food Nutr Res. 2015;59(1):25974. doi:10.3402/fnr.v59.25974.; Al Alawi M.A., Majoni S.W., Falhammar H. Magnesium and human health: perspectives and research directions. Int J Endocrinol. 2018;2018:9041694. doi:10.1155/2018/9041694.; Громова О.А., Торшин И.Ю., Рудаков К.В. и др. Недостаточность магния – достоверный фактор риска коморбидных состояний: результаты крупномасштабного скрининга магниевого статуса в регионах России. Фарматека. 2013;(6):115–29.; Блинов Д.В., Ушакова Т.И., Макацария Н.А. и др. Гормональная контрацепция и дефицит магния: результаты субанализа исследования MAGYN. Акушерство, Гинекология и Репродукция. 2017;11(1):36–48. doi:10.17749/2313-7347.2017.11.1.036-048.; Блинов Д.В., Зимовина У.В., Джобава Э.М. Ведение беременных с дефицитом магния: фармакоэпидемиологическое исследование. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2014;7(2):23–32.; Makatsariya A.D., Bitsadze V.O, Blinov D.V. et al. Pregnant women with symptoms of magnesium deficiency in Russian Federation: MAGIC 2 study results. Magnes Res. 2016;29(3):81. URL: https://www.researchgate.net/publication/316007448_Pregnant_women_with_symptoms_of_magnesium_deficiency_in_Russian_Federation_MAGIC_2_study_results.; Блинов Д.В., Зимовина У.В., Сандакова Е.А., Ушакова Т.И. Дефицит магния у пациенток с гормонально-зависимыми заболеваниями: фармакоэпидемиологический профиль и оценка качества жизни. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2015;8(2):16–24. URL: https://cyberleninka.ru/article/n/defitsit-magniya-u-patsientok-s-gormonalno-zavisimymi-zabolevaniyami-farmakoepidemiologicheskiy-profil-i-otsenka-kachestva-zhizni.; Schimatschek H.F., Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res. 2001;14(4):283–90.; De Baaij J.H.F., Hoenderop J.G.J., Bindels R.J.M. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95(1):1–46. doi:10.1152/physrev.00012.2014.; Olza J., Aranceta-Bartrina J., González-Gross M. et al. Reported dietary intake, disparity between the reported consumption and the level needed for adequacy and food sources of calcium, phosphorus, magnesium and vitamin D in the Spanish population: findings from the ANIBES study. Nutrients. 2017;9(2):168. doi:10.3390/nu9020168.; Olza J., Aranceta-Bartrina J., González-Gross M. et al. Reported dietary intake and food sources of zinc, selenium, and vitamins A, E and C in the Spanish population: findings from the ANIBES study. Nutrients. 2017;9(7):697. doi:10.3390/nu9070697.; Jahnen-Dechent W., Ketteler M. Magnesium basics. Clin Kidney J. 2012;5(Suppl 1):i3–i14. doi:10.1093/ndtplus/sfr163.; Danziger J., William J.H., Scott D.J. et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013;83(4):692–9. doi:10.1038/ki.2012.452.; Наумов Д.Е. Термочувствительные ионные каналы TRPM8 (oбзор литературы). Бюллетень физиологии и патологии дыхания. 2011;(42):89–96.; Громова О.А., Гоголева И.В. Применение магния в зеркале доказательной медицины и фундаментальных исследований в терапии. Дефицит магния и концепция стресса. Трудный пациент. 2007;5(11):29–38.; Voets T., Nilius B., Hoefs S. et al. TRPM6 Forms the Mg 2+ influx channel involved in intestinal and renal Mg 2+ absorption. J Biol Chem. 2004;279(1):19–25. doi:10.1074/jbc.M311201200.; Schlingmann K.P., Gudermann T. A critical role of TRPM channel-kinase for human magnesium transport. J Physiol. 2005;566(Pt 2):301–8. doi:10.1113/jphysiol.2004.080200.; Pilchova I., Klacanova K., Tatarkova Z. et al. The involvement of Mg 2+ in regulation of cellular and mitochondrial functions. Oxid Med Cell Longev. 2017;2017:6797460. doi:10.1155/2017/6797460.; Sontia B., Touyz R.M. Magnesium transport in hypertension. Pathophysiology. 2007;14(3–4):205–11. doi:10.1016/j.pathophys.2007.09.005.; Mutnuri S., Fernandez I., Kochar T. Suppression of parathyroid hormone in a patient with severe magnesium depletion. Case Rep Nephrol. 2016;2016:2608538. doi:10.1155/2016/2608538.; Viering D.H.H.M., de Baaij J.H.F., Walsh S.B. et al. Genetic causes of hypomagnesemia, a clinical overview. Pediatr Nephrol. 2017;32(7):1123–35. doi:10.1007/s00467-016-3416-3.; Seo J.W., Park T.J. Magnesium metabolism. Electrolyte Blood Press. 2008;6(2):86–95. doi:10.5049/EBP.2008.6.2.86.; Pham P.C.T., Pham P.-A.T., Pham S.V. et al. Hypomagnesemia: a clinical perspective. Int J Nephrol Renovasc Dis. 2014;7:219–30. doi:10.2147/IJNRD.S42054.; Lajer H., Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999;25(1):47–58. doi:10.1053/ctrv.1999.0097.; Bagnis C.I., Deray G. Amphotericin B nephrotoxicity. Saudi J Kidney Dis Transpl. 2002;13(4):481–91.; Lee C.H., Kim G.-H. Electrolyte and acid-base disturbances induced by clacineurin inhibitors. Electrolyte Blood Press. 2007;5(2):126–30. doi:10.5049/EBP.2007.5.2.126.; Sivakumar J. Proton pump inhibitor-induced hypomagnesaemia and hypocalcaemia : case review. Int J Physiol Pathophysiol Pharmacol. 2016;8(4):169–74.; Atsmon J., Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Saf. 2005;28(9):763–88. doi:10.2165/00002018-200528090-00003.; Makatsariya A.D., Dzhobava E.M., Bitsadze V.O. et al. Observational study of outpatient women in hormone dependent conditions with magnesium deficiency and receiving Magne B6® Forte in Russia (MAGYN Study). Magnes Res. 2016;29(3):82. URL: https://www.researchgate.net/publication/316007423_Observational_study_of_outpatient_women_in_hormone_dependent_conditions_with_magnesium_deficiency_and_receiving_Magne_B6_Forte_in_Russia_MAGYN_Study.; Ryu A., Kim T.H. Premenstrual syndrome : a mini review. Maturitas. 2015;82(4):436–40. doi:10.1016/j.maturitas.2015.08.010.; Rosenstein D.L., Elin R.J., Hosseini J.M. et al. Magnesium measures across the menstrual cycle in premenstrual syndrome. Biol Psychiatry. 1994;35(8):557–61. doi:10.1016/0006-3223(94)90103-1.; Sherwood R.A., Rocks B.F., Stewart A., Saxton R.S. Magnesium and the premenstrual syndrome. Ann Clin Biochem. 1986;23(Pt 6):667–70. doi:10.1177/000456328602300607.; Muneyyirci-Delale O., Nacharaju V.L., Altura B.M., Altura B.T. Sex steroid hormones modulate serum ionized magnesium and calcium levels throughout the menstrual cycle in women. Fertil Steril. 1998;69(5):958–2. doi:10.1016/S0015-0282(98)00053-3.; Tonick S., Muneyyirci-Delale O. Magnesium in women’s health and gynecology. Open J Obstet Gynecol. 2016;6(5):325–33. doi:10.4236/ojog.2016.65041.; Facchinetti F., Sances G., Borella P. et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31(5):298–301. doi:10.1111/j.1526-4610.1991.hed3105298.x.; Walker A.F., De Souza M.C., Vickers M.F. et al. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health. 1998;7(9):1157–65. doi:10.1089/jwh.1998.7.1157.; Quaranta S., Buscaglia M.A., Meroni M.G. et al. Pilot study of the efficacy and safety of a modified-release magnesium 250 mg tablet (Sincromag) for the treatment of premenstrual syndrome. Clin Drug Investig. 2007;27(1):51–8. doi:10.2165/00044011-200727010-00004.; De Souza M.C., Walker A.F., Robinson P.A., Bolland K. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med. 2000;9(2):131–9. doi:10.1089/152460900318623.; Fathizadeh N., Ebrahimi E., Valiani M. et al. Evaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome. Iran J Nurs Midwifery Res. 2010;15(Suppl 1):401–5.; Дадак К., Макацария А.Д., Блинов Д.В., Зимовина У.В. Клинические и биохимические аспекты применения препаратов магния в акушерстве, гинекологии и перинатологии. Акушерство, Гинекология и Репродукция. 2014;8(2):69–78.; Черкасова Н.Ю., Фомина А.В., Филиппова О.В. Анализ рынка лекарственных средств для лечения дисменореи. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2013;6(3):36–9.; Унанян А.Л., Алимов В.А., Аракелов С.Э. и др. Фармакоэпидемиология использования оригинального дротаверина при дисменорее: результаты международного многоцентрового исследования. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2014;7(3):44–50.; Оразов М.Р., Чайка А.В., Носенко Е.Н. Купирование хронической тазовой боли, обусловленной аденомиозом, прогестагенами нового поколения. Акушерство, Гинекология и Репродукция. 2014;8(3):6–10.; Джобава Э.М. Вопросы безопасности применения дротаверина в акушерской практике. Акушерство, Гинекология и Репродукция. 2018;12(1):54–60. doi:10.17749/2313-7347.2018.12.1.054-060.; Proctor M.L., Farquhar C.M. Dysmenorrhoea. BMJ Clin Evid. 2007;2007:0813.; Proctor M., Murphy P. A. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2001;(3):CD002124. doi:10.1002/14651858.CD002124.; Seifert B., Wagler P., Dartsch S. et al. Magnesium – a new therapeutic alternative in primary dysmenorrhea. Zentralbl Gynakol. 1989;111(11):755–60. (In German).; Parazzini F., Di Martino M., Pellegrino P. Magnesium in the gynecological practice : a literature review. Magnes Res. 2017;30(1):1–7. doi:10.1684/mrh.2017.0419.; Fontana-Klaiber H., Hogg B. Therapeutic effects of magnesium in dysmenorrhea. Schweiz Rundsch Med Prax. 1990;79(16):491–4. (In German).; Benassi L., Barletta F.P., Baroncini L. et al. Effectiveness of magnesium pidolate in the prophylactic treatment of primary dysmenorrhea. Clin Exp Obstet Gynecol. 1992;19(3):176–9.; Higdon J. An evidence-based approach to vitamins and minerals: health benefits and intake recommendations. Stuttgart, New York: Thieme, 2012. 282 p.; Olatunji L.A., Oyeyipo I.P., Micheal O.S., Soladoye A.O. Effect of dietary magnesium on glucose tolerance and plasma lipid during oral contraceptive administration in female rats. Afr J Med Med Sci. 2008;37(2):135–9.; Akinloye O., Adebayo T.O., Oguntibeju O.O. et al. Effects of contraceptives on serum trace elements, calcium and phosphorus levels. West Indian Med J. 2011;60(3):308–15.; Muneyyirci-Delale O., Nacharaju V.L., Dalloul M. et al. Divalent cations in women with PCOS: implications for cardiovascular disease. Gynecol Endocrinol. 2001;15(3):198–201. doi:10.1080/gye.15.3.198.201.; Sharifi F., Mazloomi S., Hajihosseini R. et al. Serum magnesium concentrations in polycystic ovary syndrome and its association with insulin resistance. Gynecol Endocrinol. 2012;28(1):7–11. doi:10.3109/09513590.2011.579663.; O’Shaughnessy A., Muneyyirci-Delale O., Nacharaju V.L. et al. Circulating divalent cations in asymptomatic ovarian hyperstimulation and in vitro fertilization patients. Gynecol Obstet Invest. 2001;52(4):237–42. doi:10.1159/000052982.; Bird S.T., Hartzema A.G., Brophy J.M. et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185(2):E115–20. doi:10.1503/cmaj.120677.; Громова О.А., Лиманова О.А., Торшин И.Ю. Систематический анализ фундаментальных и клинических исследований указывает на необходимость совместного использования эстроген-содержащих препаратов с препаратами пиридоксина и магния. Акушерство, Гинекология и Репродукция. 2013;7(3):35–50.; Farsinejad-Marj M., Saneei P., Esmaillzadeh A. Dietary magnesium intake, bone mineral density and risk of fracture : a systematic review and meta-analysis. Osteoporos Int. 2016;27(4):1389–99. doi:10.1007/s00198-015-3400-y.; Gur A., Colpan L., Nas K. et al. The role of trace minerals in the pathogenesis of postmenopausal osteoporosis and a new effect of calcitonin. J Bone Miner Metab. 2002;20(1):39–43. doi:10.1007/s774-002-8445-y.; Brodowski J. Levels of ionized magnesium in women with various stages of postmenopausal osteoporosis progression evaluated on the basis of densitometric examinations. Przegl Lek. 2000;57(12):714–6. (In Polish).; Дефицит магния в акушерстве и гинекологии: результаты национального совещания. Акушерство, Гинекология и Репродукция. 2014;8(2):6–10.; Солопова А.Г., Блинов Д.В., Бегович Ё. и др. Неврологические расстройства после гистерэктомии: от патогенеза к клинике. Эпилепсия и пароксизмальные состояния. 2022;14(1):54–64. doi:10.17749/2077-8333/epi.par.con.2022.115.; Блинов Д.В., Солопова А.Г., Плутницкий А.Н. и др. Организация здравоохранения в сфере реабилитации пациенток с онкологическими заболеваниями репродуктивной системы. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2022;15(1):119–30. URL: https://cyberleninka.ru/article/n/organizatsiya-zdravoohraneniya-v-sfere-reabilitatsii-patsientok-s-onkologicheskimi-zabolevaniyami-reproduktivnoy-sistemy.; Блинов Д.В., Солопова А.Г., Ачкасов Е.Е. и др. Медицинская реабилитация пациенток с климактерическим синдромом и хирургической менопаузой: вклад коррекции дефицита магния. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2022;15(4):478–90. doi:10.17749/2070-4909/farmakoekonomika.2022.159.; Блинов Д.В., Солопова А.Г., Ачкасов Е.Е. и др. Роль коррекции дефицита магния в реабилитации женщин с климактерическим синдромом и хирургической менопаузой: результаты исследования MAGYN. Акушерство, Гинекология и Репродукция. 2022;16(6):676–91. doi:10.17749/2313-7347/ob.gyn.rep.2022.371.; Блинов Д.В., Солопова А.Г., Ачкасов Е.Е. и др. Организация реабилитации пациенток с опухолями яичников: современные подходы и будущие направления. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2023;16(2):303–16. URL: https://www.elibrary.ru/ip_restricted.asp?rpage=https%3A%2F%2Fwww%2Eelibrary%2Eru%2Fitem%2Easp%3Fedn%3Ddcaony.; Блинов Д.В., Солопова А.Г., Ачкасов Е.Е. и др. Алгоритм комплексной психотерапевтической поддержки для женщин с психоневрологическими симптомами в период реабилитации после лечения злокачественных новообразований репродуктивной системы. Эпилепсия и пароксизмальные состояния. 2023;15(3):232–45. doi:10.17749/2077-8333/epi.par.con.2023.168.; Магне B6. Инструкция по медицинскому применению. ЛСР-007053/09. Режим доступа: http://www.grls.rosminzdrav.ru. [Дата доступа: 13. 01. 2024].; Магне B6 Форте. Инструкция по медицинскому применению. ЛСР-007053/09. Режим доступа: http://www.grls.rosminzdrav.ru]. [Дата доступа: 13. 01. 2024].; Дижевская Е.В. Мультидисциплинарный подход к коррекции магний-дефицитных состояний. Акушерство, Гинекология и Репродукция. 2015;9(3):68–85.; Дижевская Е.В. Обмен научными данными и экспертными мнениями по фармакотерапии в течение беременности: традиционные и современные подходы III Международный экспертный совет по проблемам дефицита магния в акушерстве и гинекологии. Акушерство, Гинекология и Репродукция. 2015;9(4):93–101.; О Пленуме Президиума Российского общества акушеров-гинекологов. Акушерство и гинекология. 2015;(5):113–5.; Громова О.А. Дефицит магния как проблема современного питания у детей и подростков. Педиатрическая фармакология. 2014;(1):20–30.; Ranade V.V., Somberg J.C. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther. 2001;8(5):345–57. doi:10.1097/00045391-200109000-00008.; https://www.gynecology.su/jour/article/view/2053

Availability: https://www.gynecology.su/jour/article/view/2053
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2024.512

Possibilities of reproductive function realization in patients with premature ovarian insufficiency ; Возможности реализации репродуктивной функции у пациенток с преждевременной недостаточностью яичников

Authors: A. Sh. Abdulaeva, P. I. Kuzmina, K. R. Bakhtiyarov, А. Ш. Абдулаева, П. И. Кузьмина, К. Р. Бахтияров

Source: Meditsinskiy sovet = Medical Council; № 4 (2024); 30-36 ; Медицинский Совет; № 4 (2024); 30-36 ; 2658-5790 ; 2079-701X

Subject Terms: мезенхимальные стволовые клетки пуповины человека, premature ovarian insufficiency, premature menopause, early menopause, hormone replacement therapy, IVF, ICSI, PRP, human umbilical cord-derived mesenchymal stem cells, преждевременная недостаточность яичников, ранняя менопауза, заместительная гормональная терапия, ЭКО, ИКСИ

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8172/7200; Research on the menopause in the 1990s. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser. 1996;866:1–107. Available at: https://pubmed.ncbi.nlm.nih.gov/8942292.; Shifren JL, Gass ML; NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038–1062. https://doi.org/10.1097/GME.0000000000000319.; InterLACE Study Team. Variations in reproductive events across life: a pooled analysis of data from 505 147 women across 10 countries. Hum Reprod. 2019;34(5):881–893. https://doi.org/10.1093/humrep/dez015.; Coulam CB, Adamson SC, Annegers JF. Incidence of Premature Ovarian Failure. Obstetrical & Gynecological Survey. 1987;42:182–183. https://doi.org/10.1097/00006254-198742030-00020.; Rostami Dovom M, Bidhendi-Yarandi R, Mohammad K, Farahmand M, Azizi F, Ramezani Tehrani F. Prevalence of premature ovarian insufficiency and its determinants in Iranian populations: Tehran lipid and glucose study. BMC Womens Health. 2021;21(1):79. https://doi.org/10.1186/s12905-021-01228-1.; Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;22(4):403–411. https://doi.org/10.1080/13697137.2019.1574738.; Mishra GD, Chung HF, Cano A, Chedraui P, Goulis DG, Lopes P et al. EMAS position statement: Predictors of premature and early natural menopause. Maturitas. 2019;123:82–88. https://doi.org/10.1016/j.maturitas.2019.03.008.; Rossetti R, Di Pasquale E, Marozzi A, Bione S, Toniolo D, Grammatico P et al. BMP15 mutations associated with primary ovarian insufficiency cause a defective production of bioactive protein. Hum Mutat. 2009;30(5):804–810. https://doi.org/10.1002/humu.20961.; Bodin L, Di Pasquale E, Fabre S, Bontoux M, Monget P, Persani L, Mulsant P. A novel mutation in the bone morphogenetic protein 15 gene causing defective protein secretion is associated with both increased ovulation rate and sterility in Lacaune sheep. Endocrinology. 2007;148(1):393–400. https://doi.org/10.1210/en.2006-0764.; Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotropic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet. 2004;75(1):106–111. https://doi.org/10.1086/422103.; Mansouri MR, Schuster J, Badhai J, Stattin EL, Lösel R, Wehling M et al. et al. Alterations in the expression, structure and function of progesterone receptor membrane component-1 (PGRMC1) in premature ovarian failure. Hum Mol Genet. 2008;17(23):3776–3783. https://doi.org/10.1093/hmg/ddn274.; Barros F, Carvalho F, Barros A, Dória S. Premature ovarian insufficiency: clinical orientations for genetic testing and genetic counseling. Porto Biomed J. 2020;5(3):e62. https://doi.org/10.1097/j.pbj.0000000000000062.; Qin Y, Jiao X, Simpson JL, Chen ZJ. Genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update. 2015;21(6):787–808. https://doi.org/10.1093/humupd/dmv036.; ACOG Committee Opinion No. 469: Carrier screening for fragile X syndrome. Obstet Gynecol. 2010;116(4):1008–1010. https://doi.org/10.1097/AOG.0b013e3181fae884.; Jiao X, Qin C, Li J, Qin Y, Gao X, Zhang B et al. Cytogenetic analysis of 531 Chinese women with premature ovarian failure. Hum Reprod. 2012;27(7):2201–2207. https://doi.org/10.1093/humrep/des104.; Ishizuka B. Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian Insufficiency (POI). Front Endocrinol (Lausanne). 2021;12:626924. https://doi.org/10.3389/fendo.2021.626924.; European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937. https://doi.org/10.1093/humrep/dew027.; Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R et al. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis. JAMA Cardiol. 2016;1(7):767–776. https://doi.org/10.1001/jamacardio.2016.2415.; Archer DF. Premature menopause increases cardiovascular risk. Climacteric. 2009;12(Suppl. 1):26–31. https://doi.org/10.1080/13697130903013452.; Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ 3rd. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–1083. https://doi.org/10.1212/01.wnl.0000276984.19542.e6.; Stuenkel CA, Davis SR, Gompel A, Lumsden MA, Murad MH, Pinkerton JV, Santen RJ. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975–4011. https://doi.org/10.1210/jc.2015-2236.; Webber L, Anderson RA, Davies M, Janse F, Vermeulen N. HRT for women with premature ovarian insufficiency: a comprehensive review. Hum Reprod Open. 2017;2017(2):hox007. https://doi.org/10.1093/hropen/hox007.; Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric. 2012;15(Suppl. 1):11–17. https://doi.org/10.3109/13697137.2012.669624.; Leite-Silva P, Bedone A, Pinto-Neto AM, Costa JV, Costa-Paiva L. Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure. Arch Gynecol Obstet. 2009;280(2):177–181. https://doi.org/10.1007/s00404-008-0881-3.; Popat VB, Calis KA, Vanderhoof VH, Cizza G, Reynolds JC, Sebring N et al. Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab. 2009;94(7):2277–2283. https://doi.org/10.1210/jc.2008-1878.; Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone Replacement Therapy Versus the Combined Oral Contraceptive Pill in Premature Ovarian Failure: A Randomized Controlled Trial of the Effects on Bone Mineral Density. J Clin Endocrinol Metab. 2016;101(9):3497–3505. https://doi.org/10.1210/jc.2015-4063.; Donnez J, Dolmans MM. Fertility Preservation in Women. N Engl J Med. 2017;377(17):1657–1665. https://doi.org/10.1056/NEJMra1614676.; Chae-Kim JJ, Gavrilova-Jordan L. Premature Ovarian Insufficiency: Procreative Management and Preventive Strategies. Biomedicines. 2018;7(1):2. https://doi.org/10.3390/biomedicines7010002.; Luyckx V, Dolmans MM, Vanacker J, Legat C, Fortuño Moya C, Donnez J, Amorim CA. A new step toward the artificial ovary: survival and proliferation of isolated murine follicles after autologous transplantation in a fibrin scaffold. Fertil Steril. 2014;101(4):1149–1156. https://doi.org/10.1016/j.fertnstert.2013.12.025.; Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;364(9443):1405–1410. https://doi.org/10.1016/S0140-6736(04)17222-X.; Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005;353(3):318–321. https://doi.org/10.1056/NEJMc055237.; Donnez J, Dolmans MM, Diaz C, Pellicer A. Ovarian cortex transplantation: time to move on from experimental studies to open clinical application. Fertil Steril. 2015;104(5):1097–1098. https://doi.org/10.1016/j.fertnstert.2015.08.005.; Practice Committee of American Society For Reproductive Medicine. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. Fertil Steril. 2012;97(2):282–284. https://doi.org/10.1016/j.fertnstert.2011.11.049.; Ding X, Liu G, Xu B, Wu C, Hui N, Ni X et al. Human GV oocytes generated by mitotically active germ cells obtained from follicular aspirates. Sci Rep. 2016;6:28218. https://doi.org/10.1038/srep28218.; Zhang C, Wu J. Production of offspring from a germline stem cell line derived from prepubertal ovaries of germline reporter mice. Mol Hum Reprod. 2016;22(7):457–464. https://doi.org/10.1093/molehr/gaw030.; Silvestris E, Cafforio P, D’Oronzo S, Felici C, Silvestris F, Loverro G. In vitro differentiation of human oocyte-like cells from oogonial stem cells: single-cell isolation and molecular characterization. Hum Reprod. 2018;33(3):464–473. https://doi.org/10.1093/humrep/dex377.; Guo K, Li CH, Wang XY, He DJ, Zheng P. Germ stem cells are active in postnatal mouse ovary under physiological conditions. Mol Hum Reprod. 2016;22(5):316–328. https://doi.org/10.1093/molehr/gaw015.; Martin JJ, Woods DC, Tilly JL. Implications and Current Limitations of Oogenesis from Female Germline or Oogonial Stem Cells in Adult Mammalian Ovaries. Cells. 2019;8(2):93. https://doi.org/10.3390/cells8020093.; Silvestris E, Minoia C, Guarini A, Opinto G, Negri A, Dellino M et al. Ovarian Stem Cells (OSCs) from the Cryopreserved Ovarian Cortex: A Potential for Neo-Oogenesis in Women with Cancer-Treatment Related Infertility: A Case Report and a Review of Literature. Curr Issues Mol Biol. 2022;44(5):2309–2320. https://doi.org/10.3390/cimb44050157.; Vo KCT, Kawamura K. Ovarian Fragmentation and AKT Stimulation for Expansion of Fertile Lifespan. Front Reprod Health. 2021;3:636771. https://doi.org/10.3389/frph.2021.636771.; Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, Hashimoto S et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod. 2015;30(3):608–615. https://doi.org/10.1093/humrep/deu353.; Kawamura K, Cheng Y, Suzuki N, Deguchi M, Sato Y, Takae S et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci U S A. 2013;110(43):17474–17479. https://doi.org/10.1073/pnas.1312830110.; Zhai J, Yao G, Dong F, Bu Z, Cheng Y, Sato Y et al. In Vitro Activation of Follicles and Fresh Tissue Auto-transplantation in Primary Ovarian Insufficiency Patients. J Clin Endocrinol Metab. 2016;101(11):4405–4412. https://doi.org/10.1210/jc.2016-1589.; Ferreri J, Fàbregues F, Calafell JM, Solernou R, Borrás A, Saco A et al. Drug-free in-vitro activation of follicles and fresh tissue autotransplantation as a therapeutic option in patients with primary ovarian insufficiency. Reprod Biomed Online. 2020;40(2):254–260. https://doi.org/10.1016/j.rbmo.2019.11.009.; Gupta S, Lodha P, Karthick MS, Tandulwadkar SR. Role of Autologous Bone Marrow-Derived Stem Cell Therapy for Follicular Recruitment in Premature Ovarian Insufficiency: Review of Literature and a Case Report of World’s First Baby with Ovarian Autologous Stem Cell Therapy in a Perimenopausal Woman of Age 45 Year. J Hum Reprod Sci. 2018;11(2):125–130. https://doi.org/10.4103/jhrs.JHRS_57_18.; Panda SR, Sachan S, Hota S. A Systematic Review Evaluating the Efficacy of Intra-Ovarian Infusion of Autologous Platelet-Rich Plasma in Patients With Poor Ovarian Reserve or Ovarian Insufficiency. Cureus. 2020;12(12):e12037. https://doi.org/10.7759/cureus.12037.

Availability: https://www.med-sovet.pro/jour/article/view/8172
https://doi.org/10.21518/ms2024-126

Features of menopausal period in HIV-positive women ; Особенности течения менопаузального периода у ВИЧ-инфицированных женщин

Authors: A. V. Samarina, M. I. Yarmolinskaya, A. V. Koloshkina, А. В. Самарина, М. И. Ярмолинская, A. B. Колошкина

Source: HIV Infection and Immunosuppressive Disorders; Том 15, № 4 (2023); 36-46 ; ВИЧ-инфекция и иммуносупрессии; Том 15, № 4 (2023); 36-46 ; 2077-9828 ; 10.22328/2077-9828-2023-15-4

Subject Terms: остеопороз у женщин, живущих с ВИЧ, symptoms of menopause, menopausal hormone therapy, osteoporosis in women living with HIV, симптомы менопаузы, менопаузальная гормональная терапия

File Description: application/pdf

Relation: https://hiv.bmoc-spb.ru/jour/article/view/850/566; ВИЧ-инфекция у взрослых. Клинические национальные рекомендации. 2020.; Andany N., Kennedy V.L., Aden M., Loutfy M. Perspectives on menopause and women with HIV // Int. J. Womens Health. 2016 Jan 11; Vol. 8. Р. 1–22. doi:10.2147/IJWH.S62615. PMID: 26834498; PMCID: PMC4716718.; Глобальная статистика по ВИЧ и СПИД — информационный бюллетень ЮНЭЙДС, 2023; Покровский В.В., Ладная Н.Н., Соколова Е.В. ВИЧ-инфекция за 2021 г. Бюллетень № 47. С. 9; Виноградова Т.Н., Бембеева Н.А., Пирогова А.В. ВИЧ-инфекция в Санкт-Петербурге по состоянию на 01.07.2023 г. Информационный бюллетень.; Bull L., Tittle V., Rashid T., Nwokolo N. HIV and the menopause: A review // Post Reprod Health. 2018. Mar; Vol. 24, No. 1. Р. 19–25. doi:10.1177/2053369117748794. Epub 2017 Dec 17. PMID: 29251186.; Smit M., Brinkman K., Geerlings S., Smit C., Thyagarajan K., Sighem Av., de Wolf F., Hallett TB; ATHENA observational cohort. Future challenges for clinical care of an ageing population infected with HIV: a modelling study // Lancet Infect Dis. 2015. Jul; Vol. 15, No. 7. Р. 810–818. doi:10.1016/S1473-3099(15)00056-0. Epub 2015 Jun 9. Erratum in: Lancet Infect Dis. 2015. Sep; Vol. 15(9. Р. 998. PMID: 26070969; PMCID: PMC4528076.; Sherr L., Molloy A., Macedo A., Croome N., Johnson MA. Ageing and menopause considerations for women with HIV in the UK // Virus Erad. 2016 Oct 5; Vol. 2, No. 4. Р. 215–218. PMID: 27781103; PMCID: PMC5075348.; Tariq S., Burns F.M., Gilson R., Sabin C. PRIME (Positive Transitions Through the Menopause) Study: a protocol for a mixed-methods study investigating the impact of the menopause on the health and well-being of women living with HIV in England // BMJ Open. 2019 Jun 5; Vol. 9, No. 6. Р. e025497. doi:10.1136/bmjopen-2018-025497. PMID: 31171548; PMCID: PMC6561408.; Ладная Н.Н., Соколова Е.В., Покровский В.В. Основные тенденции развития эпидемии ВИЧ-инфекции среди женщин в Российской Федерации в 2020 году // Актуальные вопросы ВИЧ-инфекции. Охрана здоровья матери и ребенка: международная научно-практическая конференция, Санкт-Петербург, 31 мая — 01 июня 2021 года. СПб.: Санкт-Петербургская общественная организация «Человек и его здоровье», 2021. С. 5–15. EDN UBEPTW.; Chirwa M., Ma R., Guallar C., Tariq S. Managing menopause in women living with HIV: A survey of primary care practitioners // Post Reprod Health. 2017 Sep; Vol. 23, No. 3. Р. 111–115. doi:10.1177/2053369117712181. Epub 2017 Jun 19. PMID: 28629256; PMCID: PMC5613803.; Менопауза и климактерическое состояние у женщины. Клинические национальные рекомендации. 2021.; Mishra G.D., Chung H.F., Cano A., Chedraui P., Goulis D.G., Lopes P., Mueck A., Rees M., Senturk L.M., Simoncini T., Stevenson J.C., Stute P., Tuomikoski P., Lambrinoudaki I. EMAS position statement: Predictors of premature and early natural menopause // Maturitas. 2019 May; Vol. 123. Р. 82–88. doi:10.1016/j.maturitas.2019.03.008. Epub 2019 Mar 13. PMID: 31027683.; Arinkan S.A., Gunacti M. Factors influencing age at natural menopause // Obstet Gynaecol Res. 2021 Mar; Vol. 47, No. 3. Р. 913–920. doi:10.1111/jog.14614. Epub 2020 Dec 21. PMID: 33350022.; Williams M., Richard-Davis G., Weickert A., Christensen L., Ward E., Schrager S. A review of African American women’s experiences in menopause // Menopause. 2022 Nov 1; Vol. 29, No. 11. Р. 1331–1337. doi:10.1097/GME.0000000000002060. Epub 2022 Sep 20. PMID: 36126249.; Andany N., Kaida A., de Pokomandy A., Yudin M.H., Wang L., Kennedy V.L., Webster K., Loutfy M; CHIWOS Research Team. Prevalence and correlates of early-onset menopause among women living with HIV in Canada // Menopause. 2020 Jan; Vol. 27, No. 1. Р. 66–75. doi:10.1097/GME.0000000000001423. PMID: 31688411.; Hachfeld A., Atkinson A., Stute P., Calmy A., Tarr P.E., Darling K.E.A., Babouee Flury B., Polli C., Sultan-Beyer L., Abela I.A., Aebi-Popp K.; Swiss HIV Cohort Study (SHCS). Brief Report: Does Menopause Transition Influence Viral Suppression and Adherence in Women Living With HIV? // Acquir Immune Defic Syndr. 2023 Apr 15; Vol. 92, No. 5. Р. 399–404. doi:10.1097/QAI.0000000000003158. Epub 2023 Jan 3. PMID: 36595226; PMCID: PMC9988224.; Sherr L., Molloy A., Macedo A., Croome N., Johnson MA. Ageing and menopause considerations for women with HIV in the UK. // Virus Erad. 2016 Oct 5; Vol. 2, No. 4. Р. 215–218. PMID: 27781103; PMCID: PMC5075348.; Hachfeld A, Atkinson A, Stute P. et al. Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS) // HIV Med. 2022. Vol. 23. Р. 417–425. doi:10.1111/hiv.13255.; Marincowitz C., Genis A., Goswami N., De Boever P., Nawrot T.S., Strijdom H. Vascular endothelial dysfunction in the wake of HIV and ART //FEBS. 2019 Apr; Vol. 286, No. 7. Р. 1256–1270. doi:10.1111/febs.14657. Epub 2018 Sep 28. PMID: 30220106.; Shah A.S.V., Stelzle D., Lee K.K., Beck E.J., Alam S., Clifford S., Longenecker C.T., Strachan F., Bagchi S., Whiteley W., Rajagopalan S., Kottilil S., Nair H., Newby D.E., McAllister D.A., Mills N.L. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis // Circulation. 2018 Sep 11; Vol. 138, No. 11. Р. 1100–1112. doi:10.1161/CIRCULATIONAHA.117.033369. PMID: 29967196; PMCID: PMC6221183.; Alvi R.M., Neilan A.M., Tariq N., Hassan M.O., Awadalla M., Zhang L., Afshar M., Rokicki A., Mulligan C.P., Triant V.A., Zanni M.V., Neilan T.G. The Risk for Sudden Cardiac Death Among Patients Living With Heart Failure and Human Immunodeficiency Virus // JACC Heart Fail. 2019 Sep; Vol. 7, No. 9. Р. 759–767. doi:10.1016/j.jchf.2019.04.025. Epub 2019 Aug 7. PMID: 31401096; PMCID: PMC6768556.; Abelman R.A., Mugo B.M., Zanni M.V. Conceptualizing the Risks of Coronary Heart Disease and Heart Failure Among People Aging with HIV: Sex-Specific Considerations // Curr. Treat Options Cardiovasc. Med. 2019. Jul 15; Vol. 21, No. 8. Р. 41. doi:10.1007/s11936-019-0744-1. PMID: 31309321.; Beckman J.A., Duncan M.S., Alcorn C.W., So-Armah K., Butt A.A., Goetz M.B., Tindle H.A., Sico J.J., Tracy R.P., Justice A.C., Freiberg M.S. Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease // Circulation. 2018 Jul 17; Vol. 138, No. 3. Р. 255–265. doi:10.1161/CIRCULATIONAHA.117.032647. Epub 2018 Mar 13. PMID: 29535090; PMCID: PMC6050082.; Ebeling P.R., Nguyen H.H., Aleksova J., Vincent A.J., Wong P., Milat F. Secondary Osteoporosis // Endocr. Rev. 2022 Mar 9; Vol. 43 No. 2. Р. 240–313. doi:10.1210/endrev/bnab028. PMID: 34476488.; Negredo E., Warriner A.H. Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients // Curr. Opin HIV AIDS. 2016 May; Vol. 11, No. 3. Р. 351–357. doi:10.1097/COH.0000000000000271. PMID: 26890207.; Van Ommen C.E., King E.M., Murray M.C.M. Age at menopause in women living with HIV: a systematic review // Menopause. 2021 Dec 1; Vol. 28, No. 12. Р. 1428–1436. doi:10.1097/GME.0000000000001871. PMID: 34854838.; Tariq S., Okhai H., Severn A., Sabin C.A., Burns F., Gilson R., Fox J., Gilleece Y., Mackie N.E., Post F.A., Reeves I., Rosenvinge M., Sullivan A., Ustianowski A., Miller R.F. Follicle-stimulating hormone in postmenopausal women living with HIV: a prevalence study // HIV Med. 2022 Apr; Vol. 23, No. 4. Р. 434–440. doi:10.1111/hiv.13205. Epub 2021 Nov 17. PMID: 34791781; PMCID: PMC9298721.; Prior J.C. Adaptive, reversible, hypothalamic reproductive suppression: More than functional hypothalamic amenorrhea // Front Endocrinol (Lausanne). 2022 Oct 19; Vol. 13. Р. 893889. doi:10.3389/fendo.2022.893889. PMID: 36339445; PMCID: PMC9626525.; King E.M., Nesbitt A., Albert A.Y.K., Pick N., Cote H.C.F., Maan E.J., Prior J.C., Murray M.C.M.; CIHR team on Cellular Aging and HIV Comorbidities in Women and Children (CARMA). Prolonged Amenorrhea and Low Hip Bone Mineral Density in Women Living With HIV-A Controlled Cross-sectional Study // Acquir Immune Defic Syndr. 2020 Apr 15; Vol. 83, No. 5. Р. 486–495. doi:10.1097/QAI.0000000000002282. PMID: 31914005.; Böttcher B., Seeber B., Leyendecker G., Wildt L. Impact of the opioid system on the reproductive axis // Fertil Steril. 2017 Aug; Vol. 1080, No. 2. Р. 207–213. doi:10.1016/j.fertnstert.2017.06.009. Epub 2017 Jun 29. PMID: 28669481.; Roberts R.E., Farahani L., Webber L., Jayasena C. Current understanding of hypothalamic amenorrhoea // Ther. Adv. Endocrinol Metab. 2020. Jul 30; Vol. 11. Р. 2042018820945854. doi:10.1177/2042018820945854. PMID: 32843957; PMCID: PMC7418467.; Fourman L.T., Fazeli P.K. Neuroendocrine causes of amenorrhea — an update // Clin. Endocrinol. Metab. 2015 Mar; Vol. 100, No. 3. Р. 812– 824. doi:10.1210/jc.2014-3344. Epub 2015 Jan 12. PMID: 25581597; PMCID: PMC4333037.; Cejtin H.E., Evans C.T., Greenblatt R., Minkoff H., Weber K.M., Wright R., Colie C., Golub E., Massad L.S. Prolonged Amenorrhea and Resumption of Menses in Women with HIV // Womens Health (Larchmt). 2018 Sep 14; Vol. 27, No. 12. Р. 1441–1448. doi:10.1089/jwh.2018.7046. Epub ahead of print. PMID: 30222490; PMCID: PMC6306666.; Sarri G., Pedder H., Dias S., Guo Y., Lumsden M.A. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause // BJOG. 2017 Sep; Vol. 124, No. 10. Р. 1514–1523. doi:10.1111/1471-0528.14619. Epub 2017 May 11. PMID: 28276200.; Ярмолинская М.И., Татарова Н.А., Касян В.Н., Петросян А.С. Эффективность негормональной терапии в лечении женщин с климактерическим синдромом // Российский вестник акушера-гинеколога. 2021. Т. 21, № 2. Р. 91–101. doi.org/10.17116/rosakush20212102191.; Dragovic B., Rymer J, Nwokolo N. Menopause care in women living with HIV in the UK — A review // Virus Erad. 2022. Feb 15; Vol. 8, No. 1. Р. 100064. doi:10.1016/j.jve.2022.100064. PMID: 35242357; PMCID: PMC8866072.; Ryom L., De Miguel R., Cotter A.G., Podlekareva D., Beguelin C., Waalewijn H., Arribas J.R., Mallon P.W.G., Marzolini C., Kirk O., Bamford A., Rauch A., Molina J.M., Kowalska J.D., Guaraldi G., Winston A., Boesecke C., Cinque P., Welch S., Collins S., Behrens G.M.N.; EACS Governing Board. Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021 // HIV Med. 2022 Sep; Vol. 23, No. 8. Р. 849–858. doi:10.1111/hiv.13268. Epub 2022 Mar 25. PMID: 35338549; PMCID: PMC9545286.; Chang C.J., Chan Y.L., Pramukti I., Ko N.Y., Tai T.W. People with HIV infection had lower bone mineral density and increased fracture risk: a meta-analysis // Arch. Osteoporos. 2021 Feb 27; Vol. 16, No. 1. Р. 47. doi:10.1007/s11657-021-00903-y. PMID: 33638754.; Finnerty F., Walker-Bone K., Tariq S. Osteoporosis in postmenopausal women living with HIV // Maturitas. 2017. Jan; Vol. 95. Р. 50–54. doi:10.1016/j.maturitas.2016.10.015. Epub 2016 Nov 5. PMID: 27889053; PMCID: PMC5363814.; Cabrera D.M., Cornejo M.P., Slotkin R., Pinedo Y., Yu W., Guan W., Garcia P.J., Hsieh E. Prevalence of and risk factors for vertebral fracture and low bone mineral density among Peruvian women aging with HIV // Arch Osteoporos. 2023. May 10; Vol. 18, No. 1. Р. 64. doi:10.1007/s11657-023-01250-w. PMID: 37160770; PMCID: PMC10170032.; Marincowitz C., Genis A., Goswami N., De Boever P, Nawrot T.S., Strijdom H. Vascular endothelial dysfunction in the wake of HIV and ART // FEBS. 2019 Apr; Vol. 286, No. 7. Р. 1256–1270. doi:10.1111/febs.14657. Epub 2018 Sep 28. PMID: 30220106.; Hoy J.F., Grund B., Roediger M., Schwartz A.V., Shepherd J., Avihingsanon A., Badal-Faesen S., de Wit S., Jacoby S., La Rosa A., Pujari S., Schechter M., White D., Engen N.W., Ensrud K., Aagaard P.D., Carr A.; INSIGHT START Bone Mineral Density Substudy Group. Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial // Bone Miner Res. 2017 Sep; Vol. 32, No. 9. Р. 1945–1955. doi:10.1002/jbmr.3183. Epub 2017 Jun 26. PMID: 28650589; PMCID: PMC5555813.; Biver E. Osteoporosis and HIV Infection // Calcif Tissue Int. 2022. May; Vol. 110, No. 5. Р. 624–640. doi:10.1007/s00223-022-00946-4. Epub 2022 Jan 30. PMID: 35098324; PMCID: PMC9013331.; Chirwa M., Taghinejadi N., Macaulay G., Mandalia S., Bellone C., Panay N., Brum R., Nwokolo N. Reflections on a specialist HIV menopause service: Experiences of managing menopause in women living with HIV: Experiences of managing menopause in women living with HIV // HIV Med. 2022 Apr; Vol. 23, No. 4. Р. 426–433. doi:10.1111/hiv.13256. PMID: 35249262.; Tittle V., Bull L., Boffito M., Nwokolo N. Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives // Clin. Pharmacokinet. 2015 Jan; Vol. 54, No. 1. Р. 23–34. doi:10.1007/s40262–014–0204–8. PMID: 25331712.; Santoro N., Roeca C., Peters B.A., Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options // Clin. Endocrinol. Metab. 2021. Jan 1; Vol. 106, No. 1. Р. 1–15. doi:10.1210/clinem/dgaa764. PMID: 33095879.; Solomon D., Sabin C.A., Burns F., Gilson R., Allan S., de Ruiter A., Dhairyawan R., Fox J., Gilleece Y., Jones R., Post F., Reeves I., Ross J., Ustianowski A., Shepherd J., Tariq S. The association between severe menopausal symptoms and engagement with HIV care and treatment in women living with HIV // AIDS Care. 2021 Jan; Vol. 33, No. 1. Р. 101–108. doi:10.1080/09540121.2020.1748559. Epub 2020 Apr 11. PMID: 32279528; PMCID: PMC8043570.; Hamoda H., Panay N., Pedder H., Arya R., Savvas M. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women // Post. Reprod Health. 2020. Dec; Vol. 26, No. 4. Р. 181–209. doi:10.1177/2053369120957514. Epub 2020 Oct 12. PMID: 33045914.

Availability: https://hiv.bmoc-spb.ru/jour/article/view/850
https://doi.org/10.22328/2077-9828-2023-15-4-36-46

On the use of sex steroids in women during the COVID-19 pandemic: The consensus position statement of professional medical associations: Ukrainian Society of Gynecological Endocrinology, Association of Obstetricians-Gynecologists of Ukraine, Association of Pharmacologists of Ukraine, Association of Anesthesiologists of Ukraine, Association of Vascular Surgeons, Phlebologists and Angiologists of Ukraine

Authors: T.F. Tatarchuk, Z.M. Dubossarska, V.I. Pyrohova, N.Y. Pedachenko, T.M. Tutchenko, O.О. Yefimenko, N.V. Kosei, Y.O. Dubossarska, K.L. Shatylovych, V.M. Zaporozhan, V.V. Kaminskyi, G.V. Zaichenko, S.A. Dubrov, L.M. Chernukha

Source: REPRODUCTIVE ENDOCRINOLOGY. :9-16

Subject Terms: менопаузальная гормональная терапия, combined hormonal contraceptives, venous thromboembolism, 3. Good health, 03 medical and health sciences, angiotensin-converting enzyme 2 receptors, 0302 clinical medicine, комбинированные гормональные контрацептивы, венозная тромбоэмболия, рецепторы ангиотензинпревращающего фермента 2, незарегистрированные рецептурные биоидентичные гормональные средства, menopausal hormonal therapy, unregistered compounded bioidentical hormonal agents

File Description: application/pdf

Access URL: http://reproduct-endo.com/article/download/232680/231426
http://reproduct-endo.com/article/view/232680
http://reproduct-endo.com/article/download/232680/231426

ESTIMATION OF THE EFFICIENCY OF HORMONE-REGULATING SYNCHRONIZATION OF OVULATION IN FEMALE MICE

Authors: V. M. Pokrovsky, E. A. Patrakhanov, P. R. Lebedev, A. V. Belashova, A. Yu. Karagodina, A. A. Shabalin, A. V. Nesterov, V. A. Markovskaya, M. V. Pokrovsky

Source: Фармация и фармакология (Пятигорск), Vol 8, Iss 4, Pp 255-262 (2021)

Subject Terms: 0301 basic medicine, 0303 health sciences, физиология животных, estrous cycle, прогестерон, синхронизация овуляции, мыши, estrus, эструс, RM1-950, биология, progesterone, эстральный цикл, ovulation synchronization, prostaglandin f2α, 03 medical and health sciences, гормональная терапия, вагинальная цитология, Therapeutics. Pharmacology, vaginal cytology, простагландин F2α

Access URL: https://www.pharmpharm.ru/jour/article/download/731/626
https://doaj.org/article/5870f219e77f410b9c31a9de32e89c95
https://www.pharmpharm.ru/jour/article/viewFile/731/626
https://www.pharmpharm.ru/jour/article/view/731/642

Hormone therapy for postmenopausal women

Authors: Pinkerton, J. V.

Source: Репродуктивная эндокринология, Vol 0, Iss 56, Pp 100-106 (2020)
Reproductive Endocrinology; № 56 (2020); 100-106
Репродуктивная эндокринология; № 56 (2020); 100-106
Репродуктивна ендокринологія; № 56 (2020); 100-106

Subject Terms: hormone therapy, гормональная терапия, менопаузальная гормональная терапия, менопауза, постменопауза, Estrogen Replacement Therapy, Age Factors, menopausal hormone therapy, menopause, Breast Neoplasms, Sweating, Gynecology and obstetrics, Middle Aged, 3. Good health, Postmenopause, postmenopause, Administration, Intravaginal, 03 medical and health sciences, 0302 clinical medicine, Cardiovascular Diseases, гормональна терапія, менопаузальна гормональна терапія, Hot Flashes, Practice Guidelines as Topic, RG1-991, Humans, Female, Selective Serotonin Reuptake Inhibitors

File Description: application/pdf

Access URL: http://reproduct-endo.com/article/download/222117/222293
https://zenodo.org/record/4419661/files/Hormone%20therapy%20for%20postmenopausal%20women.pdf
https://pubmed.ncbi.nlm.nih.gov/31995690
https://doaj.org/article/3f7d9ed14b844b69b451b744d0bcc39f
http://reproduct-endo.com/article/view/222117
http://reproduct-endo.com/article/download/222117/222293
https://www.scilit.net/article/f6ff227c7bb366d9e3a3614ea8364a92
https://eleccionesenecuador.com/doi/full/10.1056/NEJMcp1714787
https://pubmed.ncbi.nlm.nih.gov/31995690/
https://www.nejm.org/doi/suppl/10.1056/NEJMcp1714787/suppl_file/nejmcp1714787_appendix.pdf
https://www.nejm.org/doi/full/10.1056/NEJMcp1714787
https://www.ncbi.nlm.nih.gov/pubmed/31995690
https://europepmc.org/article/MED/31995690
http://reproduct-endo.com/article/view/222117